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ABSTRACT 
 
Human papillomavirus (HPV) is one of the most common sexually transmitted 
infections worldwide and affects approximately 300 million new individuals each 
year. HPV is considered the primary etiological agent involved in the development of 
cervical cancer and causes half a million cases per year worldwide. Prevention of 
genital HPV infection through immunization has led investigators to employ a 
number of strategies to develop candidate HPV vaccines. Until today, two different 
vaccines are available on the market: a quadrivalent vaccine that protects against 
HPV types 16, 18, 6, and 11 (Gardasil®, Merck Sharp and Dohme), and a bivalent 
vaccine that protects against HPV types 16 and 18 (Cervarix™, Glaxo SmithKline). 
Current data regarding the efficacy of these vaccines derive mainly from studies 
performed by the manufacturers and standardized assays are not commercially 
available to measure HPV immunity.  
In this context, the aim of this PhD research project is to set up and standardize 
HPV pseudovirion-based neutralization (PBNA) and enzyme-linked immunosorbent 
(ELISA) assays and to use these tests to evaluate and compare the immunogenicity 
and cross-reactivity levels of the two prophylactic HPV vaccines, which are offered 
free in Italy to 12-year old girls and are recommended to women aged 12-45 years, 
according to World Health Organization (WHO) guidelines.  
First, pseudovirions of HPV types 6, 11, 16, 18, 31, 45, 52, 58  were obtained with a 
titer of 109 transducing units/ml and neutralization and ELISA assays standardized. 
Subsequently, a cross sectional study to evaluate the humoral immune response 
against HPV-volunteers, adolescents, and healthy vaccinated adults with Gardasil® 
or Cervarix™ was approved by ethics committee of University Hospital of Padua. 
Comprehensive results were obtained from a group of 100 subjects from Veneto 
Region, where the quadrivalent Gardasil® vaccine was offered. The study group 
included 81 subjects investigated within 1-6 months after the completion of the three 
doses of vaccine and 7, 7, and 5 subjects investigated at 2, 3, and 4 years after 
vaccination, respectively.  
At 1-6 months after the completion of the vaccination cycle, 100% vaccinees had 
neutralizing antibodies (NAbs) against HPV16, 98,8% had NAbs against HPV18, 
while 91% had NAbs against HPV6 and 50% had NAbs against HPV11. The NAbs 
titer ranged widely from 1:40 to over 1:10,240 and was lower for NAbs against 
HPV6 and HPV11 as compared with NAbs titers against HPV16 and HPV18. A 
progressive reduction of NAbs titer was observed over time and, at 4 years from 
vaccination, 80% of subjects had NAbs against HPV16, HPV18 and HPV6, and 60% 
against HPV11. Low level cross-NAbs titer against HPV31 (1:40) was detected in 
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50% (3/6) of subjects at 1-6 months after vaccination, while no cross-NAbs were 
detected against HPV45, HPV52 and HPV58.  
We also evaluated the presence of HPV type-specific NAbs in a group of 6 young 
girls vaccinated with CervarixTM at 1-6 months after the completion of the 
vaccination cycle. All subjects presented specific NAbs against HPV16 and HPV18. 
Titers were higher as compared with titers observed in Gardasil® vaccinated 
subjects. 100% of subjects presented also cross-NAbs against HPV31, whereas 
16,6% presented cross-NAbs against HPV45 and HPV58. None presented cross-
NAbs against HPV52. 
Thanks to these results we can conclude that high-level NAbs were induced with 
both Gardasil® and CervarixTM vaccines. For the first vaccine, we observed the 
decline of NAbs titers and the limited cross-neutralization against HPV31. For the 
second one, cross-neutralizing NAbs were observed against HPV31 in all subjects, 
together with the presence of NAbs against HPV45 and HPV58 in some subjects. 
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RIASSUNTO 
 
L'infezione da papilloma virus umano (HPV) è una delle più comuni infezioni 
trasmesse per via sessuale in tutto il mondo e colpisce circa 300 milioni di nuovi 
individui ogni anno. L’infezione persistente da tipi di HPV definiti ad alto rischio è la 
causa necessaria per lo sviluppo del cancro del collo dell’utero. Annualmente, 
vengono registrati circa 500.000 casi di carcinomi del collo dell’utero in tutto il 
mondo. La necessità di prevenire questo tipo di infezione ha portato nel corso degli 
ultimi anni allo sviluppo di diverse strategie vaccinali. Ad oggi, sono disponibili due 
diversi vaccini profilattici: un vaccino quadrivalente che protegge contro HPV16, 18, 
6, e 11 (Gardasil®, Merck Sharp & Dohme), e un vaccino bivalente che protegge 
contro HPV 16 e 18 (Cervarix™, Glaxo SmithKline). I dati riguardanti l'efficacia e 
l’immunogenicità di questi due vaccini derivano principalmente da studi effettuati 
dalle ditte produttrici.  Non sono disponibili inoltre test standardizzati commerciali in 
grado di valutare l'immunità nei confronti dei diversi tipi di HPV.  
Obiettivo di questo progetto di ricerca di dottorato è quello di sviluppare e 
standardizzare un test specifico per la ricerca di anticorpi anti-HPV basato sulla 
neutralizzazione di diversi tipi di HPV mediante pseudovirioni (PBNA) e un test 
immunoenzimatico (ELISA), e di utilizzare questi test per valutare e confrontare i 
livelli di immunogenicità e cross-reattività dei due vaccini profilattici anti-HPV che 
sono offerti gratuitamente in Italia alle ragazze nel loro dodicesimo anno di età e che 
vengono raccomandati per le donne di età compresa tra i 12 e i 45 anni, secondo le 
linee guida dell'Organizzazione Mondiale della Sanità (OMS).  
A tal fine, sono stati prodotti diversi lotti di pseudovirioni corrispondenti ai tipi 
HPV6, 11, 16, 18, 31, 45, 52, 58 con un titolo pari a 109 unità trasducenti/ml e sono 
stati standardizzati i saggi di neutralizzazione tipo-specifica e il saggio ELISA. E’ 
stato disegnato uno studio cross-sectional per valutare la risposta immunitaria umorale 
contro i diversi tipi di HPV in soggetti sani, adolescenti e adulti, vaccinati con 
Gardasil® o Cervarix™.  
I risultati sono stati ottenuti analizzando un gruppo di 100 soggetti della Regione 
Veneto, dove era offerta la vaccinazione con Gardasil®. In particolare, sono stati 
esaminati 81 soggetti a distanza di 1-6 mesi dal completamento del ciclo vaccinale, 7 
soggetti valutati a 2 anni dalla vaccinazione, 7 soggetti a 3 anni dalla vaccinazione, e 5 
a 4 anni dalla vaccinazione.  
A distanza di 1-6 mesi dal completamento della vaccinazione con Gardasil®, il 100% 
dei soggetti  presentava  anticorpi neutralizzanti contro HPV16, il 98,8% contro 
HPV18, il 91% contro HPV6 e il 50% contro HPV11. Sono stati ottenuti titoli di 
anticorpi neutralizzanti compresi tra 1:40 e 1:10,240. I titoli osservati nei confronti di 
HPV6 e HPV11 sono risultati inferiori rispetto a quelli osservati nei confronti di 
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HPV16 e HPV18. E’ stata, inoltre, osservata una riduzione progressiva nel titolo in 
base al tempo intercorso dall’ultima dose vaccinale. A 4 anni dalla vaccinazione, 
l'80% dei soggetti presentava anticorpi neutralizzanti contro HPV16, HPV18 e 
HPV6, mentre il 60% nei confronti di HPV11. Per quanto riguarda la presenza di 
anticorpi cross-neutralizzanti, è stato osservato un titolo pari a 1:40 nei confronti di 
HPV31 nel 50% (3/6) dei soggetti entro i primi 6 mesi dalla vaccinazione, mentre 
non sono stati rilevati anticorpi cross-neutralizzanti nei confronti di HPV45, HPV52 
e HPV58.  
E' stata valutata, inoltre, la presenza di anticorpi neutralizzanti nei confronti dei 
diversi tipi di HPV in un gruppo di 6 ragazze vaccinate con CervarixTM  a distanza di 
1-6 mesi dal completamento della vaccinazione. Tutti i soggetti presentavano 
anticorpi neutralizzanti nei confronti di HPV16 e HPV18, a titoli più elevati rispetto 
ai titoli osservati nei soggetti vaccinati con Gardasil®. Il 100% dei soggetti 
presentava, inoltre, anticorpi cross-neutralizzanti contro HPV31, mentre il 16,6% 
aveva anticorpi cross-neutralizzanti contro HPV45 e HPV58. Nessun soggetto ha 
presentato anticorpi cross-neutralizzanti contro HPV52. 
In conclusione, entrambi i vaccini sono in grado di indurre elevati livelli di specifici 
anticorpi neutralizzanti i tipi di HPV vaccinali. Per quanto riguarda il vaccino 
Gardasil® è stata osservata una diminuzione dei titoli anticorpali nel tempo e una 
limitata cross-neutralizzazione nei confronti di HPV31. Per quanto riguarda il 
vaccino CervarixTM, invece, è stata osservata la presenza di anticorpi cross-
neutralizzanti contro HPV31 in tutti i soggetti, unitamente alla presenza degli 
anticorpi neutralizzanti contro HPV45 e HPV58 in alcuni soggetti. 
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1. INTRODUCTION 
 
1.1. Human papillomaviruses 
 
Human papillomaviruses (HPVs) are small, non-enveloped viruses that belong to the 
Papillomaviridae family. HPVs comprise five evolutionary groups with different 
epithelial tropisms and disease associations. Alpha papillomaviruses include low-risk 
mucosal types that cause genital warts, and high-risk mucosal types that can cause 
cervical pre-cancer and cancer (Figure 1). Although cutaneous HPV types (Alpha, 
Beta and Gamma) are not generally associated with cancer, certain Beta types have 
been implicated in the development of non-melanoma skin cancers (NMSC) in 
immunosuppressed individuals and in epidermodysplasia verruciformis (EV) 
patients.  
 
 
Figure 1. Evolutionary relationship between HPVs (adapted from Doorbar et al., 2012). 
 
The genome of HPVs is composed by a circular double-stranded DNA molecule of 
8 kilobases (kb). Viral capsid consists of two main structural proteins, L1 (called 
major) and L2 (called minor), both with late expression. At molecular level, L1 
sequence is the most conserved among different genotypes of HPVs such as N-
terminal domain of L2 sequence (Gambhira et al., 2007; Pereira et al., 2009). More 
than 150 HPV types have been completely sequenced and classified on the basis of 
major capsid protein L1 differences in the amino acid sequence (de Villiers et al., 
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2004; Bernard et al., 2010; see Papillomavirus Episteme (PaVE); 
http://pave.niaid.nih.gov/#home). L1 proteins are also able to self assemble 
forming virus-like particles (VLPs) (IARC, 2007), while L2 proteins are internally 
located with roles in genome encapsidation, L1 interaction and capsid stabilization, 
endosomal escape of virions and nuclear transport of HPV genome. Assembled 
particles contain 360 molecules of L1 arranged into 72 pentameric capsomeres linked 
via disulphide bonds, with a much smaller and variable number of L2 molecules, 
which can occupy capsomeres at the 5-fold axis of symmetry. Viral genome is 
composed by other six early expression proteins: E5, E6, E7 with cellular 
proliferation, survivor and carcinogenesis functions and E1, E2, E4 with 
transcriptional control and viral replication involvement (Figure 2). In particular, E7 
protein is responsible of Rb destruction and progression in S-phase of cellular cycle, 
while E6 protein interferes with pro-apoptotic factors p53 and Bak and activates 
telomerase enzyme.  
 
 
Figure 2. HPV structure and genome (adapted from zur Hausen, 2002). 
 
At pathogenetic level, HPV infection is one of the most common sexually 
transmitted infections worldwide and affects around 300 million new individuals 
each year. Twelve HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are defined 
by the WHO as being high-risk cancer causing types (category 1, according to IARC 
classification), with additional types (68, 73) being recognized as possibly cancer-
causing (category 2, according to IARC classification). Together, these viruses cause 
approximately half a million cases of cervical cancer per year worldwide, with 
approximately half of these being fatal (WHO/ICO Information Centre on Human 
Papilloma Virus and Cervical Cancer; http://www.who.int/hpvcentre/en/). In 
particular, HPV types 16 and 18 cause approximately 70% of all cervical cancers 
(Day et al., 2007; Villa, 2011). Other oncogenic HPV types, including HPV types 31, 
33, 35, 45, 52 and 58, account for additional 18% of all cervical cancers (Figure 3) 
(Stanley et al., 2006; Lu et al., 2011; Crow, 2012). 
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Figure 3. HPV and cervical cancer (adapted from WHO/ico information. 
Center on HPV and cervical cancer. http://www.nature.com/nature/journal/v488/). 
 
Prospective studies have shown that women persistently infected with high-risk HPV 
types are at a significantly greater risk of developing cervical intraepithelial neoplasia 
(CIN) compared with women who are only transiently infected (Schlecht et al., 2003). 
HPV 16 is found in about half of cervical tumors examined and is strongly associated 
with CIN, carcinoma in situ (CIS), squamous intraepithelial lesions (SIL) and cervical 
cancer. Importantly, all fourteen HPV types mentioned before, are also associated 
with cancers at other sites, including the penis in men, the vagina and vulva in 
women and, in both genders, the anal transformation zone, the tonsils, oropharynx 
and base of tongue (D’Souza et al., 2007; Giuliano, Tortolero-Luna et al., 2008). 
Deregulation of viral gene expression may occur to different extents at different sites 
of high-risk HPV infection, and that squamo-columnar junctions, such as the cervical 
transformation zone, are particularly prone to neoplastic disease. Nevertheless, high-
risk HPVs do not cause cancer in the vast majority of the individuals that they infect 
(Doorbar, 2006; zur Hausen, 2009). The natural history of HPV infection in men has 
also been evaluated. A recent study has shown that genital HPV infection is common 
and multifocal in young men, and its incidence seems to be higher than previously 
reported (Giuliano, Lazcano-Ponce et al., 2008). The low-risk types HPV6 and 
HPV11 are responsible for anogenital warts, which are common in the general 
population (Brown et al., 1999), and for a rare but severe and potentially lethal 
disease, i.e., recurrent respiratory papillomatosis (RRP) (Wiatrak, 2003). 
 
1.2. Mechanism of  HPV infection 
 
Papillomaviruses are species-specific viruses with a strong tropism for epithelial 
tissues such as skin and mucosa. Their process of infection is interesting and, in 
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some ways, unique. Penetration of the virus occurs in the basal layer of the 
epithelium, following cuts or abrasions. Experimental models suggest that infection 
requires access of virus particles to the basal lamina, and the interaction with heparan 
sulphate proteoglycans (HSPGs) (Combita et al., 2001; Giroglou et al., 2001; Johnson 
et al., 2009) and possibly also laminin (Culp et al., 2006). Structural changes in the 
virion capsid, which includes furin cleavage of L2, facilitate transfer to a secondary 
receptor on the basal keratinocyte, which is necessary for virus internalization and 
subsequent transfer of the viral genome to the nucleus (Richards et al., 2006; Kines et 
al., 2009; Schiller et al., 2010; Bienkowska-Haba et al., 2009). Although the Alpha 6 
Integrin and growth factor receptors have been implicated in this process (Evander et 
al., 1997; McMillan et al., 1999; Shafti-Keramat et al., 2003; Licitra et al., 2006; 
Scheurer et al., 2007; Surviladze et al., 2012), the precise nature of the entry receptor 
remains somewhat controversial (Patterson et al., 2005; Sapp et al., 2009; Schiller et al., 
2010; Horvath et al., 2010; Surviladze et al., 2012) (Figure 4).  
 
 
 
 
Figure 4. HPV initial infection steps (adapted from Schiller et al., 2010).  The virion first 
binds to HSPGs on the base membrane exposed after disruption (A). This induces a 
conformational change exposing a site on L2 susceptible to furin cleavage (B). After L2 
cleavage, an L2 neutralizing epitope is exposed and a previously unexposed region of L1 
binds to an unidentified secondary receptor on the invading edge of the epithelial cells (C).  
 
Once internalized, virions undergo endosomal transport, uncoating, and cellular 
sorting. The L2 protein-DNA complex ensures the correct nuclear entry of the viral 
genomes, while the L1 protein is retained in the endosome and ultimately subjected 
to lysosomal degradation (Bergant Marušič et al., 2012; Schelhaas et al., 2012) (Figure 
5). 
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Figure 5. HPV virion processing after cell entry (adapted from Schiller et al., 2010).  After 
initial binding to HSPGs and furin cleavage, the virus is transferred to an unidentified 
receptor on the cell surface (A). The virus then enters the cell via an endocytic pathway (B) 
and within 4 hours localizes in the early endosome (C). By 12 hours, the virus uncoats within 
the late endosome, and the viral genome complexed with L2 is released (D). The L2–genome 
complex traffics through the cytoplasm, perhaps via microtubules, and enters the nucleus by 
24 hours (E). After nuclear entry, the complex co-localizes with ND10 and RNA 
transcription begins (F).  
 
After the entry into the nucleus, the genome of HPV can remain in an episomal state 
at low copy number (about 100 copies per cell). Viral genome is able to replicate and 
segregate into daughter cells persisting in the episomal state until basal cells 
(keratinocytes) migrate to higher levels, such as differentiated layers (spinous and 
granular layers of squamous epithelium). Thanks to E6 and E7 oncoproteins, HPV 
stimulates the proliferation of differentiated cells, thus ensuring its survival and 
replication. Finally, with the production of L1 and L2 proteins, new mature virions 
can form (Figure 6). Although not precisely defined, the abundant E4 protein is 
thought to contribute to virion release and infectivity in the upper epithelial layers, as 
it assembles into amyloid fibres that disrupt keratin structure and compromise the 
normal assembly of the cornified envelope (Wang et al., 2004; Brown et al., 2006; 
McIntosh et al., 2008). Time between infection and release of mature virions is 
approximately 3 weeks. This gap is necessary for the differentiation of keratinocytes 
and desquamation. Subsequently, in a period ranging between weeks and months, 
benign lesions such as warts or papillomas arise. These formations often regress 
spontaneously. However, sometimes, the lesions may persist and evolve, giving rise 
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to tumor formation, such as warts, laryngeal papillomas and cervical cancers 
(Kanodia et al., 2007). 
 
 
 
 
Figure 6. Mechanism of HPV infection (adapted from zur Hausen, 2002). 
 
1.3. HPV and the immune system 
 
Most cervical HPV infections are transient, resolving within 1 to 2 years in 70-90% 
of cases (Steben and Duarte-Franco, 2007), implying that the host immune system 
must play an important role in preventing, controlling and eliminating HPV infection 
at the cervix. In some cases, the immune system is unable to control the infection, 
thus persistent infection is established and viral DNA can be found in the cervix for 
at least 6-12 months. This situation may lead to the development of high-grade 
cervical intraepithelial lesions (CIN2/3) that may progress to achieve invasive 
properties. In general, during infection, innate immunity, cell-mediated immunity 
(CMI) and humoral immunity play a key role in the response at entry and replication 
phases, although it is not yet known the exact sequence in which one follows after 
the other. Neutralizing antibodies are believed to be the main effectors of protection 
against infection, preventing the initial entry of virus and internalization into basal 
epithelial cells. On the other hand, clearance of infection is thought to be mediated 
predominantly by cellular immunity. At humoral level, antibodies are directed against 
conformational epitope(s) in the variable regions of the major viral coat protein L1 
displayed on the outer surface of the intact virus particle and are the only ones that 
can neutralize the viral particles circulating at extracellular level. After natural 
infection, humoral response is very slow and weak, with low levels of detectable 
type-specific antibodies to L1 in about 50-70% of infected individuals (Viscidi et 
al.,1997; Carter et al., 2000). Seroconversion appears to occur 6-18 months following 
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infection, defined as detection of HPV DNA. The presence of HPV L1-specific 
antibodies can be considered as marker for past or current infection, because they are 
frequently detected in subjects with persistent infections and precancerous lesions 
(Mariani and Venuti, 2010). Most serologic studies have focused only on 
immunoglobulin G (IgG) antibody concentrations. Isotype-specific serum antibody 
responses against HPV16 have been evaluated in a few cross-sectional, prospective, 
and population-based seroepidemiological studies. IgG1 and immunoglobulin A 
(IgA) are the most abundant isotypes in natural infection. IgA is induced earlier, and 
does not appear to be as persistent as the IgG response after HPV DNA clearance 
(van Doornum et al., 1998). However, not all individuals develop serum antibodies 
after HPV infection, and protection degree and duration in those subjects who 
seroconverted are still unknown. In addition, some of these individuals remain 
susceptible to re-infection with the same viral type. In this context, memory B cells 
are essential for protection against subsequent re-infections by the same 
papillomavirus type (Schiller et al., 2008) and CMI responses against HPV proteins 
may participate in early defense against HPV infection. In particular, T helper 
responses play a key role in antiviral cytokines release (i.e. IFN gamma; TNF alfa) 
which contribute to inhibition and control of infection and in the generation and 
maintenance of protective B cell responses. Cytotoxic T lymphocytes (CTL) 
responses against L1 may also be important for maximization of the prophylactic 
efficacy by eliminating or limiting the number of HPV-infected cells that have 
escaped antibody neutralization. In contrast, HPV has implemented a series of 
strategies to evade immune responses and many of them are dependent from its 
replication cycle. In fact, HPV has only intraepithelial and not cytolytic replication. 
Therefore, there is no viremia or systemic infection development and the expression 
of viral proteins does not reach detectable levels. In addition, pro-inflammatory 
cytokines are released to activate dendritic cells, but no inflammatory reactions arise. 
In fact, interferon response is suppressed by viral oncoproteins E6 and E7 of high-
risk HPV types, such as HPV16 and down-regulation of the toll-like receptor 9 
expression (TLR9) by the  E7 protein has been recently reported (Schwartz, 2008). In 
this scenario, the innate immune response is compromised and the adaptive immune 
response delayed.  
 
1.4. Prophylactic HPV L1 VLP vaccines 
 
A number of strategies to develop candidate HPV vaccines to prevent or treat genital 
HPV infection through immunization have been investigated (Schiller et al., 2001). 
Back in the nineties, the first proof-of-principle clinical trials were conducted with 
extremely positive results: administration of papillomaviruses L1 self-assembled 
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VLPs protected against infections and diseases caused by common papillomavirus, in 
a type specific manner. High titers of neutralizing antibodies are induced by VLP 
vaccines as measured by type-specific antibody responses to each HPV VLP in 
different immunogenicity studies (Villa, 2007). From the first studies to licensing of 
HPV prophylactic vaccines only about 15 years passed by. Two vaccines have been 
developed and are available for clinical use, a quadrivalent vaccine that protects 
primarily against HPV16, 18, 6, and 11 (Gardasil®, Merck Sharp and Dohme), and a 
bivalent vaccine that protects primarily against HPV16 and 18 (CervarixTM, Glaxo 
SmithKline). Both vaccines are composed of HPV L1 proteins assembled into VLPs; 
they are produced in different cells (via recombinant Saccharomyces pombe vector and 
via recombinant baculovirus vector, respectively) and contain different adjuvants 
(proprietary alum adjuvant for Gardasil® and ASO4 adjuvant comprising 500 g of 
aluminium hydroxide and 50 g of 3-deacylated monophosphoryl lipid A for 
Cervarix™). Both are administered by intramuscular injection, in three doses (0, 1 or 
2 and 6 months), and are generally well tolerated (Harper et al., 2004; Villa et al., 
2005). Systemic immunization with L1 VLPs generates antibody concentrations 1-4 
logs higher than those measured in natural infections (Harro et al., 2001); this is most 
likely due to the route of immunization and antigen concentration. Some clinical 
trials have also reported the vaccine efficacy after fewer than three doses of the 
bivalent vaccine (Kreimer et al., 2011). Most common vaccine-related adverse events 
were local transient mild to moderate pain and erythema at the site of injection. The 
proportion of women experiencing serious adverse events was much the same in 
vaccinated and placebo recipients. Although women were encouraged to use reliable 
methods of birth control, pregnancies did occur in numerous women enrolled in the 
trials. Overall, there was no difference in pregnancy outcomes, including congenital 
abnormalities, between VLP vaccines and placebo for either vaccines. In fact, none 
of the serious adverse events referred either in clinical trials or post-licensure have 
been related to the vaccines (Slade et al., 2009). Both vaccines are able to induce the 
expected memory B cell response, which is a characteristic of vaccines with durable 
immune responses (Olsson et al., 2007). In one study, memory B cell responses 
appeared to correlate with neutralization titers, but not with antibody avidity (Dauner 
et al., 2010). Long-term follow-up studies have shown that efficacy is maintained for 
at least 7 years, and modeling studies suggest protection may last much longer (Villa 
et al., 2006a; Lehtinen et al., 2006). Both vaccines were shown to be highly 
immunogenic in clinical trials, resulting in essentially 100% seroconversion in the 
different populations studied. Peak geometric mean antibody titers (GMTs) were 
approximately 10- to 100-fold higher that the GMTs generated after natural infection 
(Villa et al., 2006b; Schwarz et al., 2008). Several clinical trials of two prophylactic 
HPV vaccines have been conducted in different countries including approximately 
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50.000 individuals. Phase III trials were blinded, randomized, and placebo-controlled 
and included young (mean age 20 years old) and adult women (up to 55 years old) 
and more recently also men (16-23 years old) from different countries worldwide. 
Prophylactic efficacy was measured considering HPV infection and disease 
endpoints, particularly CIN2 or worse (CIN2+) for the bivalent and quadrivalent 
vaccines, as well as Vulvar Intraepithelial Neoplasia (VIN) or Vaginal Intraepithelial 
Neoplasia (VaIN) and genital warts, for the quadrivalent vaccine only. In these trials, 
HPV DNA assays and antibody measurements were applied both to defining naïve, 
HPV-susceptible per-protocol populations and to determine the effects of 
vaccination, although only 50% of individuals mount an immune response after 
natural exposure to HPV. The per-protocol populations included women who were 
naïve at baseline to HPV16 and 18, or to HPV6, 11, 16, and 18, as determined by 
serology testing for the presence of HPV type-specific antibodies or polymerase 
chain reaction (PCR) testing of genital samples for the presence of HPV DNA. For 
both the bivalent and quadrivalent vaccines, very high prophylactic efficacies 
(approximately 100%) were recorded (Harper et al., 2004; Villa et al., 2005; Harper et 
al., 2006; Future II Study Group, 2007;  Ault et al., 2007; Joura et al., 2007; Paavonen 
et al., 2007; Einstein et al., 2011a). Recently, the bivalent vaccine was demonstrated to 
induce significantly higher anti-HPV16 and 18 neutralizing antibody titers in women 
aged 27-45 years at all time points through to month 24, as compared to the 
quadrivalent vaccine. Moreover, higher anti-HPV16 and 18 neutralizing antibody 
titers have been observed in younger age groups (18-26 years old and 27-35 years 
old) compared with the older age group (36-45 years old) at all time points from 
month 7 to 24 (Einstein et al., 2011a). These results confirmed previous observations, 
by Reisenger and Pedersen regarding higher immune response observed in children 
and adolescent than in adults (Reisinger et al., 2007; Pedersen et al., 2007). As 
expected from observations in other studies for both vaccines, levels of vaccine-
induced anti-HPV16 and 18 antibodies peaked at month 7 and subsequently declined 
toward plateau by month 18 (Einstein et al., 2011a). Anyway, prior or prevalent 
infection by one HPV type did not appear to influence the effectiveness of the 
vaccine against other types (Hildesheim et al., 2007). Cross-protection against 
incident infection with HPV type 31 has been observed for both the bivalent and the 
quadrivalent vaccines (Ault, 2007). For additional HPV types different levels of 
protection were recorded (Bonanni et al., 2009). In particular, Einstein and 
collaborators (Einstein et al., 2011b) demonstrated that both vaccines are able to 
induce cross-reactive serologic responses against HPV31 and HPV45, but at lower 
titer than those for vaccine types HPV16/18. These finding are in line with cross-
protection efficacy against infections and lesions associated with HPV 31, 33, and 45 
that has been reported for the bivalent vaccine (Malagon et al., 2012). At month 24, 
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there were no significant differences between the bivalent vaccine and the 
quadrivalent vaccine in terms of anti-HPV31/45 circulating antibodies (Einstein et 
al., 2011b). However, it should be noted that circulating neutralizing antibodies were 
at levels close to or below the limit of detection of each assay (Einstein et al., 2011b).  
 
1.5. Immune correlates of protection 
 
Data from published clinical trials on HPV L1 VLP vaccines demonstrate clearly that 
both the bivalent and quadrivalent vaccines protect the vaccinees from persistent 
cervical HPV16/18 infection and cervical HPV16/18-induced disease. The 
quadrivalent vaccine also protects women against HPV6/11-induced mucosal and 
cutaneous genital disease. The mechanisms of protection are not fully understood. 
VLPs are highly immunogenic and VLP-immunized individuals have anti-VLP 
antibody responses substantially greater (at least 1-4 logs) than in natural infections. 
In natural infections, L1 antibody levels are low and there is probably little or no 
viraemia and no evolutionary pressure on the virus to escape the antibody response. 
In contrast to natural infection, L1 VLP vaccines are delivered by intramuscular 
injection, which allows antigens to gain access to the draining lymphatics and small 
vessels at the injection site, thereby effectively mimicking a viraemia. One can 
speculate that this explains, in part, the intensity of the antibody responses induced 
by these HPV L1 VLP vaccines (Stanley et al., 2006; Stanley et al., 2012). Although a 
direct correlation between antibody levels and protection may seem intuitively 
obvious, it is still unclear whether differing antibody titers indicate better disease 
protection or longer duration of immune protection (Schwarz and Leo, 2008). Given 
that virtually all vaccinated women are seroconverted and the vaccines are highly 
efficacious, to date there is no immune correlate of protection against infection or 
disease; the minimum level of antibody needed for such protection and the role of B 
cell memory if antibody wanes have yet to be established (Stanley et al., 2012). As 
already stated in the last WHO position paper, the question still remains unanswered 
(WHO position paper No 15, 2009). Only long-term follow up of vaccinated cohorts 
in human populations could answer such questions unequivocally.  
 
1.6. Next generation HPV vaccines 
 
Neutralizing antibodies evocated by vaccines based on HPV L1 are type-restricted 
and there is limited cross-reactivity. On the other hand, minor capsid protein L2 does 
not evoke a neutralizing antibody response in natural infections. However, deliberate 
immunization with L2 protein has been demonstrated to generate neutralizing 
antibodies that are protective against viral challenge in cows and rabbits. Importantly, 
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these antibodies have been implicated in cross-neutralization of a broad range of 
mucosal and cutaneous HPV types, suggesting that an L2 vaccine could act as a pan-
HPV vaccine (Karanam et al., 2009). However, protein vaccines such as L2 are 
considered  as poorly immunogenic, as compared to the L1 VLPs. In fact, L1-based 
VLPs are optimal immunogens both in terms of particle size, which allow easy 
transfer across endothelium into lymphatics, and in terms of geometry of the highly 
organized pentamer repeat structure across the capsid, which induces robust 
antibody and memory responses in all B cell subsets. Recent studies have focused on 
strategies to enhance L2 immunogenicity by multimerisation, epitope display and 
adjuvantation. In a recent report, mice immunised with a concatenated multitype L2 
fusion protein with a variety of different adjuvants, including alum, generated robust 
antibody concentrations that were only slightly lower than those elicited by 
commercially available VLP vaccines (Jagu et al., 2009). The L2 vaccine is due to 
enter phase I clinical trials in early 2013 (Nieto et al., 2012). Many efforts have been 
done to develop therapeutic vaccines. These vaccines generally targets E6 and E7 
oncoproteins. A prototype vaccine that contains whole E7 proteins from the five 
most common cancer-causing HPV types, as well as poly(I:C) - a double-stranded 
RNA molecule that signals the presence of a virus has been generated. Together E7 
and poly(I:C) stimulate a swift build-up of CD8. In addition, the whole-protein 
formulation of this vaccine, called Pentarix, makes it more stable than the minimal 
peptide approaches, without the need for refrigeration, thus rendering it useful for 
developing-world settings (Wick and Webb, 2011). 
 
1.7. Immunoassays 
 
Measurement of specific serum antibodies anti-L1 VLP by immunoassays in 
vaccinated and unvaccinated individuals is the main parameter used in the current 
vaccine trials to monitor vaccine-induced immune responses. The methodologies 
that have been used in the quadrivalent Gardasil® vaccine trials differ from those 
employed in the evaluation of the bivalent Cervarix™ vaccine and direct 
comparisons of antibody responses to the different vaccines are therefore not 
feasible yet. For the quadrivalent vaccine, serum antibodies against HPV6, 11, 16 and 
18 were measured using a competitive radioimmunoassay (cRIA) or a competitive 
Luminex immunoassay (cLIA). In brief, in the cRIA, polystyrene beads are coated 
with a limiting amount of VLP antigen and incubated with the corresponding HPV 
type-specific, neutralizing, mouse monoclonal antibody (MAb), and the serum 
sample. The amount of MAbs bound to the VLP antigen is measured after 
incubation with 125I-labelled goat anti-IgG. In the cLIA, HPV L1 VLPs are 
conjugated to Luminex microspheres and incubated with phycoerythrin labelled type-
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specific neutralizing MAbs and a serum sample. The amount of bound dye is 
quantified with a Luminex100 Biopex instrument. These competitive assays measure 
only those serum antibodies that bind to, or compete with, the single neutralizing 
epitope that binds the MAbs on the specific VLPs and are not a measurement of 
total serum anti-L1 VLP IgG. A disadvantage of such assays is that, since affinities of 
binding and other parameters of antibody–antigen interaction will differ between the 
different MAbs used, direct comparisons of antibody titers generated by the different 
VLPs (HPV 6, 11, 16, 18 VLPs) in the vaccine cannot be made. The advantages of 
the competitive assays are that neutralizing antibody is assayed specifically, the 
antibody response to each VLP is measured in the same test and, in general in such 
assays, backgrounds are low, sensitivity is enhanced and spurious cross-reactions are 
reduced. For the bivalent HPV16/18 vaccine, measurement of serum antibody to 
HPV16 and 18 VLPs was performed using a conventional ELISA. In this assay, 
microwell plates coated with purified recombinant HPV16 or 18 VLPs are incubated 
with serial dilutions of sera, the bound antibody reacted with horseradish peroxidase 
(HRP) conjugated goat anti-human IgG and the colour intensity is quantified by 
optical density measurements. The advantages of such assay are that total serum anti-
VLP IgG is measured and direct comparisons can be made between responses to 
individual VLPs. A disadvantage is that the antibody response to individual VLPs is 
assayed in separate tests, the fraction of serum IgG attributable to neutralizing 
antibody specifically cannot be quantified, but the available data suggest that 
neutralizing and ELISA antibodies titers are usually highly correlated. At the present, 
the gold standard method to evaluate specific antibody responses is a neutralization 
assay based on pseudovirion (PBNA). This test involves the use of pseudovirion 
made by L1 and L2 proteins of different HPV types (HPV type 6, 11 16 18, etc.)  
containing a reporter gene, such as alkaline phosphatase. To test neutralizing titers in 
serum samples, target cells (293TT) are seeded firstly, and then serum and 
pseudovirion are added. After 72 hours of incubation, supernatants are collected to 
measure alkaline phosphatase activity using a luminometer. Neutralizing titers are 
expressed as the dilution of serum in which there is 50% reduction in alkaline 
phosphatase activity. Other methods, just as important for assessing the response of 
memory B cells and CD4+ T cells, are based on the use of ELISPOT assays. B-cell 
ELISPOT assay is able to quantify HPV-specific memory B cells after differentiation 
into plasma cells secreting antibodies in vitro, as well as to determine the production 
of IFN-γ and IL-10. Mononuclear cells or B lymphocytes are purified from 
peripheral blood samples and 96-well plates are pre-adsorbed with the specific HPV 
VLPs. Mononuclear cells or B cells are added to the plates and left at 37 °C for 
several hours. During the incubation secreted antibodies bind to the VLPs. Cells are 
then removed and a secondary biotinylated antibody directed against human 
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immunoglobulins is added to the plates. The subsequent addition of streptavidin and 
chromogenic substrate allows the detection of immune complexes and the 
quantification of the spots. Reading is performed by an ELISPOT reader. T-cell 
ELISPOT assay allows to evaluate cellular immunity induced by the vaccination, 
analyzing T cells that produce IFN-γ. Specific monoclonal antibodies are 
immobilized on the bottom of 96-well plates. To stimulate the production of 
cytokines, cells under examination are incubated with the CD4 or CD8 epitopes of 
the L1 protein of HPV. Secreted cytokines are then immobilized by the antibodies 
on the bottom of the wells and their detection occurs after a washing step, adding a 
secondary biotinylated antibody or conjugated with an enzyme. The subsequent 
addition of the substrate allows the registration of spots corresponding to active T 
cells by the ELISPOT reader. 
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2. AIM OF THE STUDY 
 
Available data regarding HPV vaccine efficacy and immunogenicity derive mainly 
from studies performed by the manufacturer companies. In addition, standardized 
assays are not commercially available to measure HPV immunity. In this context, the 
development of standardized tests for the evaluation of antibody immune response 
after vaccination and the design of independent studies comparing the 
immunogenicity of the two vaccines could provide new useful diagnostic tools and 
scientific data to support national and regional public health authorities in the 
evaluation of vaccination programs.  
The main purpose of this PhD research project is to set up and standardize HPV 
pseudovirion-based neutralization assays (PBNA) and ELISA assays, and to use 
these assays to compare the immunogenicity of the two prophylactic HPV vaccines 
which are currently offered in Italy, in terms of neutralizing and cross-neutralizing 
antibody titers. No comparative data on the immunogenicity of two vaccines in the 
target population of adolescent girls are yet available in the literature. Moreover, no 
data from independent studies comparing efficacy and immunogenicity of 
prophylactic HPV vaccines have been published until now. Therefore, insights 
emerging from this 3-year project will provide information on the humoral immune 
response after the completion of three vaccine doses and at long-term follow-up 
which could be useful to decide if further booster doses are required. The assessment 
on the possible different levels of cross-protection against non-vaccinal high-risk 
HPV types induced by two vaccines is another important evaluation from this study. 
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3. MATERIALS AND METHODS 
 
MATERIALS 
 
3.1. Cell line 
 
Cell line used for transfection and transduction experiments in this project consists 
of an adenovirus-transformed human embryonic kidney cell line with a stably 
integrated Simian vacuolating virus 40 (SV40) genome, called 293TT, kindly provided 
by the groups of Professor Chris Buck and Professor John Schiller at the National 
Cancer Institute - Center for Cancer Research (NCI-CCR) in Bethesda, USA. These 
engineered cells constitutively express the SV40 Large T antigen. This line supports 
high level replication of plasmids containing the SV40 origin of replication (ori).  Co-
transfection of 293TT cells with plasmids containing strong eukaryotic promoters 
driving codon modified L1 and L2, together with the pseudogenome plasmid 
containing the SV40 ori and a marker gene, results in assembly of reporter 
pseudovirions in the nucleus of the transfected cell. The growth medium suitable for 
the maintenance of these cells is Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) inactivated at 56 °C, 1% non-
essential amino acids and 1% Glutamax (Invitrogen™). The cells were also subjected 
to selection with the antibiotic hygromycin B 250 µg/ml (Invitrogen™), in order to 
promote the maintenance of T antigen. Cell cultures were maintained at 37 °C in a 
humidified 5% CO2 atmosphere. 
 
3.2. Plasmids 
 
Plasmids used in this study were kindly provided by the groups of Professor Chris 
Buck and Professor John Schiller at NCI-CCR in Bethesda, USA. Plasmids contain 
the coding sequences of viral structural proteins of different HPV types necessary for 
the virions formation that are not replication-competent (p6shell, p11shell.L1, 
p11shell.L2, p16shell, p18shell, p31shell, p45shell, p52shell and p58shell). Plasmid 
containing sequences of two different reporter genes were also used (pfwb 
containing the coding sequence of enhanced green fluorescence protein (EGFP), and 
pYSEAP containing the coding sequence of human placental alkaline phosphatase 
protein (SEAP)). All plasmids were amplified in high-efficiency commercial 
prokaryotic cells (MAX Efficiency®Stbl2™ Competent Cells, Invitrogen™). 
Bacteria were grown in TB medium (Terrific Broth: Bacto tryptone, yeast extract, 
glycerol and phosphate buffer) shaking at 30 °C. 
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3.3. Study subjects 
 
Serum samples were obtained from 100 female subjects aged between 12 and 46 
years old (mean age: 15,66 years old) who completed the vaccination with Gardasil® 
at different time points (1-6 months, 2 years, 3 years and 4 years). Blood samples 
were collected at Microbiology and Virology Unit of Padova University Hospital. To 
all the participants, or to a parent in the case of a minor, was required to subscribe an 
informed consent. Other 11 non-vaccinated subjects (8 males and 3 females, aged 
between 24 and 47 years old) tested positive for molecular research HPV were 
included in the study, as well as a vaccinated female and a vaccinated male as first 
control experiments. Thanks to a kind collaboration with Microbiology and Virology 
Unit of Sant’Orsola Malpighi University Hospital of Bologna, we included also 6 
female serum samples (age range: 11-20 years old; mean age: 13,99 years old), 
collected 1-6 months after the completion of vaccination cycle with  Cervarix™ . All 
blood samples were centrifuged at 3000 rpm for 10 minutes and sera were then 
aliquoted and stored at -20 °C until use. 
 
METHODS  
 
3.4. Bacterial transformation 
 
HPV DNA plasmids were incubated with 100 µl of competent bacteria on ice for 30 
minutes. Subsequently, bacteria were subjected to thermal shock by exposure to 42 
°C for 25 seconds, cooled on ice and incubated at 30 °C for 90 minutes in 900 µl of 
SOC medium (Invitrogen™), allowing the expression and the synthesis of the 
protein that confers resistance to the antibiotic selection. Finally, 100 µl of 1:40 
diluted suspension were seeded in Petri dishes containing LB-agar supplemented 
with ampicillin 100 mg/ml or alternatively with blasticidin 100 g/ml or with 
kanamycin 25 mg/ml, depending on the selection, and incubated 16 hours at 30 °C 
in order to select transformed bacteria. 
 
3.5. Plasmid DNA preparation 
 
To obtain plasmid preparations of high purity and large-scale (maxi prep) suitable for 
transfection of eukaryotic cells, the plasmid DNA was extracted using alternatively 
the QIAGEN Plasmid Maxi Kit or QIAfilter Plasmid Maxi kit based both on the use 
of anion exchange columns by QIAGEN®. Through this process plasmid DNA 
binds to the resin column using buffers with low salt concentration and is purified 
from RNA, proteins and high molecular weight impurities. Plasmid DNA is then 
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eluted from the column by buffers at high salt concentration. Subsequently, the 
plasmid is concentrated by precipitation with isopropanol and then washed with 
ethanol 70% (v/v). DNA was quantified by spectrophotometric reading with 
NanoDropND 1000 Spectrophotometer (ThermoScientific) at the wavelength of 260 
nm, corresponding to the maximum absorption peak of the nitrogenous bases. 
Contaminations have been detected by the reading of the preparation at a wavelength 
of 280 nm, corresponding to the maximum absorption peak of the peptide bond. 
 
3.6. Enzyme restriction  
 
Different DNA restriction reactions were performed using the appropriate enzymes 
in their reaction buffer (Biolabs). p16shell, p58shell, p18shell, p45shell plasmids were 
assessed by digestion with the restriction enzyme PstI, p31shell with EcoRI, p6shell 
with ClaI, p52shell with EcoRI, p11shell.L1 and p11shell.L2 with BamHI, pYSEAP 
with SacI, pfwb with NcoI. The reactions were conducted at the optimum 
temperature of the enzyme (37 °C in all cases) for about 2 hours. An aliquot of the 
digestion products was controlled by electrophoretic migration in agarose gel 1% 
(w/v) using 20X TBE buffer (11 mM Tris base, boric acid, 5.5 mM EDTA, 0.5 M 
pH 8) to determine the correct restriction. 
 
3.7. Transfection of 293TT cells 
 
In this experimental work, lipofection method was used to transfect 293TT cells. 
Cells were seeded at a density of 7x104 in 6-well plates in 4 ml of DMEM medium 
without antibiotics, but enriched in serum. This operation was performed 24 hours 
before the lipofection, in order to achieve a perfect confluence of 30-50% of the 
cells. Next day, cells were transfected with 4 µg of each plasmid in conjunction with 
4 µg of pfwb plasmid or pYSEAP plasmid using 12 µl of Lipofectamine™ 2000 (1 
mg/ml, Invitrogen™) according to the manufacturer's instructions. 
 
3.8. Production of HPV VLPs containing EGFP and SEAP reporter genes 
 
Different HPV VLPs, containing L1 and L2 coding sequences of different HPV 
types and EGFP or SEAP reporter genes, were produced by lipofection of 293TT 
cells with p6shell, p11shell.L1, p11shell.L2, p16shell, p18shell, p31shell, p45shell, 
p52shell, p58shell and pfwb or pYSEAP plasmids (see paragraphs 3.2. and 3.7.). 
VLPs that are released from 293TT cells lysis are immediately infectious, but require 
further maturation overnight at 37 °C to assume the correct conformation. For this 
purpose, 48 hours after lipofection 293TT cells were tripsinized, counted and 
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resuspended in DPBS-Mg. The lysate was then incubated for 24 hours at 37 °C with 
1/20th of a volume of 10% Triton X-100. All manipulations of transfected cells and 
their lysates were carried out under a laminar flow hood type BL2. Following 
maturation, the lysate was partially frozen at -80 °C and partially purified by 
polyacrilamide desalting column (see paragraph 3.9.). 
 
3.9. Extraction and purification of the salts by Optiprep or polyacrilamide 
desalting column 
 
Before Optiprep (Sigma®) or polyacrylamide desalting column (Thermo Scientific 
Pierce) purification, cell lysates containing VLPs were subjected to salt extraction. 
Lysates were incubated on ice, 5 M NaCl was added and cells were centrifuged at 
10.000 g for 10 minutes. Supernatant was centrifuged, and stratified on the Optiprep 
gradient or on a pre-balanced desalting column. Optiprep gradient is made of 
solution containing 60% iodixanol appropriately diluted with DPBS/NaCl in order 
to obtain 27%, 33% and 39% iodixanol solutions and to be placed in 5 ml 
ultracentrifuge tubes. Lysates were subjected to ultracentrifugation stratification at 
50.000 rpm at 16 °C for 3,5 hours. After that, different fractions were collected. 
Purification with polyacrilamide desalting column was made by subsequent elutions 
with buffer containing DPBS and 0.5 M NaCl.  
 
3.10. Screening of the fractions 
 
Fractions obtained after ultracentrifugation and layered with Optiprep were analyzed 
using Quant-iT PicoGreen dsDNA assay. This assay allows to assess the presence of 
DNA encapsidation, thanks to the permeability of these capsids to small solutes, 
such as fluorescent markers of DNA. In addition, fractions containing L1 protein, 
which are the most represented in the central fractions of the gradient (4-8), were 
analyzed by SDS-PAGE in non-reducing conditions. L1 content was also quantified 
by spectrophotometric reading with NanoDropND 1000 Spectrophotometer 
(ThermoScientific) at the wavelength of 280 nm, corresponding to the maximum 
absorption peak of the peptide bond. 
 
3.11. Quantification of cell extracts 
 
Protein content in cell lysate was determined by a colorimetric assay (Pierce-
ThermoScientific), followed by the quantification with the spectrophotometer. The 
assay exploits the property of bicinchoninic acid (BCA), provided in the form of 
sodium salt, to react with high sensitivity with copper ions (Cu1+) to form a water-
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soluble reaction product of purple color, characterized by an absorption maximum at 
wavelength of 492 nm. Copper ions (Cu1+) are made available in an alkaline 
environment owing to the interaction between proteins and Cu2+ ions (Biuret 
reaction). Since the reaction product is directly proportional to the total amount of 
protein present in the reagents, it is possible to quantify proteins by 
spectrophotometric analysis. For each sample, 10 µl of cell extracts were taken and 
seeded in 96-well plates (Falcon ®) in order to be incubated with 200 µl of the 
mixture of kit reagents. After an incubation of 30 minutes at 37 °C, the reaction 
product was quantified at the spectrophotometer and the total amount of proteins 
was extrapolated by comparing results with a calibration curve obtained with known 
amounts of bovine serum albumin. 
 
3.12. Western blotting  
 
In order to assess the presence and the expression of HPV16 L1 and L2 proteins in 
cells transfected with p16shell plasmid or transduced with HPV16 VLPs, Western 
blotting analysis using specific antibodies anti-HPV16 L1 (CamVir-1, Santa Cruz 
Biotechnology) and anti-HPV16 L2 (2JGmab#4, Santa Cruz Biotechnology, Inc.) 
were performed. Resolving and stacking gels were prepared at 10% of SDS in both 
cases. Protein extracts/elutions were loaded into gel after denaturation with β-
mercaptoethanol. After gel running at a constant speed of 100 V, gels were 
transferred on a nitrocellulose membrane at 350 mA for 1 hour. Subsequently, 
saturation was performed overnight with a solution containing TBS 1X, 0.1% Tween 
and 1% or 5% of milk, respectively. Next day, membranes were washed with TBS 1X 
and 0.1% Tween solution. Blotting with the primary antibody anti-HPV16 L1 
(CamVir-1, Santa Cruz Biotechnology) or anti-HPV16 L2 (2JGmab#4, Santa Cruz 
Biotechnology, Inc.) was performed for 4 or 1 hour respectively, followed, only in 
the case of p16shell and HPV16 VLPs, by the addition of  goat secondary antibody 
anti-mouse IgG-HRP (Santa Cruz Biotechnology). Finally, the membrane was 
observed after revelation with ECL chemiluminescent substrate at VersaDoc 
instrument (Biorad). 
 
3.13. Transduction of 293TT cells with VLPs 
 
293TT cells were transduced with HPV VLPs (see paragraph 3.8.). One day before 
the transduction, 1.5x105 cells were seeded in 24-wells plates in 0.5 ml of DMEM 
medium supplemented with serum and antibiotics. Then, cells were transduced with 
1 µl of matured and purified supernatant (see paragraphs 3.8. and 3.9.). 48 hours after 
 26 
 
transduction, cells were detached with trypsin and assessed by flow cytometry and 
immunofluorescence (see paragraphs 3.14. and 3.15.) 
 
3.14. Flow cytometry 
 
293TT transfected cells with p16shell and pfwb plasmids and 293TT transduced cells 
with VLPs were collected, resuspended in 300 µl of PBS and analyzed by FACS 
instrument (Becton-Dickinson, Rutherford, NJ). The analysis was conducted in a 
manner that would prevent at least 99,8% of non-transfected and non-transduced 
cells as control cells. Viral titer evaluation was made by selecting dilutions of VLPs 
with a positivity rate given by the fluorescent marker (EGFP) varying between 1% 
and 25%. The formula that was used is the following: 
[Fraction of positive cells] x [N. inoculated cells] x [1000 µl/ml] x [dilution of the 
stock]. 
 
3.15. Immunofluorescence 
 
293TT transfected cells with p16shell and pfwb plasmids and 293TT transduced cells 
with VLPs were evaluated by fluorescence microscopy with and without the primary 
antibody anti-HPV16 L1 (CamVir-1, Santa Cruz Biotechnology). After fixation with 
a solution containing dimethyl ketone at 95% and three washes with PBS and water, 
cells were stained with the specific antibody. After washing, cells were stained with 
fluorescein isothiocyanate (FITC) and observed under a fluorescence microscope by 
using various objectives. 
 
3.16. Chemiluminescence assay for secreted alkaline phosphatase detection  
 
Expression of alkaline phosphatase activity resulting from transfection of 293TT 
cells with pYSEAP plasmid or from transduction of 293TT cells with different HPV 
types VLPs encapsidating SEAP reporter plasmid was assessed by two 
chemiluminescence assays (SEAP Chemiluminescence Kit 2.0 Great Escape, 
Clontech; SEAP Reporter Gene Assay, Roche). Both assays provide an analysis of 
cell supernatant in which alkaline phosphatase is secreted after 18 hours of 
transfection or 72 hours of transduction. After been tested, we decided to used the 
second one, by Roche, because of its feasibility and reproducibility. Supernatants 
were diluted with a suitable buffer ready for use and then incubated in a thermal 
cycler at 65 °C for 30 minutes. After a centrifugation of 30 seconds at 13.000 rpm, 
supernatants were cooled on ice and mixed with an inactivation buffer onto 96-well 
micro white plate. After an incubation at room temperature for 5 minutes, substrate 
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was added and supernatants incubated at room temperature for 10 minutes. Finally, 
the reading was performed with a luminometer, set at Glow-Endpoint 0.20 sec/well. 
 
3.17. Pseudovirion-based neutralization assay (PBNA) 
 
VLPs encapsidating SEAP reporter plasmid were used to develop in vitro 
pseudovirion-based neutralization assay presented below. VLPs transduction of 
293TT cells is monitored by SEAP activity in cell culture supernatant using a highly 
sensitive chemiluminescent reporter system (see paragraph 3.16.). Antibody-mediated 
VLPs neutralization is detected by a reduction in SEAP activity. This neutralization 
assay is adapted to a high-throughput 96 well plate format. Firstly, 293TT cells were 
counted and dilute to obtain 300.000 cells/ml in neutralization buffer (DMEM 
without phenol red, 10% of FBS, 1% of Glutamax™, 1% of non essential amino-
acids). 100 µl of cells were dispensed in each well of a 96-well plate and incubated for 
2-5 hours at 37 °C. Meanwhile, each type of HPV VLPs were diluted in 
neutralization buffer, as well as sera (1:40, 1:160, 1:640, 1:2,560, 1:10,240, 1:20,480). 
Control antibodies were also prepared (i.e. J4 for HPV 18 1:20.000, 1:100.000; D9 
1:10.000, 1:20.000, 1:50.000, 1:100.000; V5 for HPV 16 1: 20.000, 1:100.000). HPV16 
positive serum was used as a positive neutralization control at dilution of 1:80. After 
3 hours of incubation, 80 µl of VLPs mixed with different dilution of 20 µl of serum 
or antibody or heparin as positive neutralization control were cooled on ice for 1 
hour. Then, the mixture was added to the cells. After 72 hours, supernatant was 
finally used in chemiluminescence assay for secred alkaline phosphatase detection 
(see paragraph 3.16.).  
 
3.18. Enzyme-linked immunosorbent assay (ELISA)  
 
In a specific ELISA assay, intact HPV16 VLPs (0,5 µg, 1 µg) were coated onto 
microtiter plates in PBS at pH 7.2. Coating was performed overnight at 4 °C. After 
washing with PBS-Tween, plate was blocked at room temperature for 1 hour with 
PBS-BSA. After washing with PBS-Tween, serum samples diluted in PBS-BSA (1:10, 
1: 31,6, 1:100) were added for 2 hours at room temperature. After five washing steps 
with PBS-Tween, specific anti-human IgHRP (γchain) antibody (dilution 1:1.000) 
was added to the plate for 1 hour at room temperature. After five washing steps with 
PBS-Tween, substrate was added and incubated for 30 minutes at room temperature. 
After blocking agent addiction, plate was read at 450/620 nm.  
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4. RESULTS 
 
4.1. Production of HPV pseudovirions: summary of results 
 
For this study, pseudovirion-based neutralization assay (PBNA), which is considered 
the gold standard method for the evaluation of the immune response against HPV was 
developed. To this purpose, constructs containing the structural proteins of different 
types of HPV (kindly provided by Professor Chris Buck and Professor John Schiller 
groups at the NCI-CCR in Bethesda, USA) were used  to produce different types of 
HPV VLPs consisting of L1 and L2 proteins. VLPs containing EGFP and SEAP 
reporter plasmids were produced on small scale in 293TT hygromycin-selected cells. 
VLPs were then purified by using Optiprep gradient and evaluated for their 
transfecting and transducing capability. Structural informations of VLPs were also 
obtained by non-denaturing SDS-page followed by Western blotting analysis. Viral 
titer was evaluated by flow citometry (109 transducing units/ml).  
 
4.1.1. Production of plasmids containing different HPV types sequences and 
EGFP and SEAP reporter genes  
 
All plasmids containing sequences of the structural genes L1 and L2 of different 
HPV types and plasmids containing the sequences of reporter genes, i.e. EGFP and 
SEAP, were produced in quantities between 1 and 4 µg/µl by transformation into 
high efficiency prokaryotic cells (see paragraphs 3.2. and 3.4.) and subsequent 
extraction with QIAGEN Plasmid Maxi kit or QIAfilter Plasmid Maxi kit (see 
paragraph 3.5.). The quantification was carried out at the NanoDrop 2000 
(ThermoScientific). The correctness of plasmids sequence was assessed by restriction 
enzyme (see paragraph 3.6.). Examples of p16shell, p18shell, p11shell.L1, p11shell.L2 
and pYSEAP enzymatic restrictions are reported in figure 7. 
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Figure 7. Examples of plasmid restrictions: p16shell plasmid after enzymatic restriction with 
PstI (1); uncut p16shell plasmid (2); uncut p18shell plasmid (3); p18shell plasmid after 
enzymatic restriction with PstI (4); uncut p11shell.L2 plasmid (5); p11shell.L2 plasmid after 
enzymatic restriction with BamHI (6); uncut p11shell.L1 plasmid (7); p11shell.L1 plasmid 
after enzymatic restriction with BamHI (8); uncut pYSEAP plasmid (9); pYSEAP plasmid 
after enzymatic restriction with SacI (10); molecular weight markers (11-12). 
 
4.1.2. Evaluation of alkaline phosphatase expression by using a 
chemiluminescence assay in 293TT cells 
 
Unselected and hygromycin-selected 293TT cells for 15 days were transfected with 
the positive control provided by the Great Escape kit (see paragraph 3.16.) in order 
to evaluate the transfection efficiency by the expression of alkaline phosphatase. 
Supernatants were collected 24, 48 and 72 hours after transfection and then 
processed and analyzed according to the manifacture's protocol. Chemiluminescence 
reading was performed by using different luminometers, one provided by Diagene 
and one by Promega. The results, in terms of raw luminescence (RLU: relative light 
unit), led to the conclusion that hygromycin-selected 293TT cells had the best 
transfection efficiency. Subsequently, unselected and hygromycin-selected 293TT 
cells for 15 and 30 days were transfected with pYSEAP plasmid (see paragraphs 3.2. 
and 3.7.). After luminometer reading we were able to conclude that transfection was 
carried out correctly and reading time was critical, as we observed a decrease in the 
chemiluminescence signal over time. 293TT cells selected with hygromycin for 15 
days were the best for our experiments, according to the protocols of NCI-CCR, and 
were used for all the experiments here reported. 
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4.1.3. Evaluation of EGFP reporter gene expression in transfected cells 
 
293TT cells selected with hygromycin for 15 days and unselected were transfected 
with pfwb plasmid in order to assess EGFP expression by the reporter. Direct 
observation of cells at fluorescence microscope (Leica 6500CTR HS) or after fixation 
in dimethyl ketone at 95% showed that 50-60% of cells were EGFP-positive (figure 
8). 
 
 
Figure 8. Direct observation of 293TT cells transfected with pfwb plasmid at fluorescence 
microscope: negative control (top), unselected (middle), hygromycin selected cells for 15 
days (bottom). 
 
4.1.4. Evaluation of HPV16 L1 protein expression in transfected cells 
 
In order to observe the expression of HPV16 L1 protein in hygromycin-selected 
293TT cells, cells were transfected with p16shell plasmid in single and coupled with 
pfwb plasmid. Subsequently, cells were harvested, fixed in dimethyl ketone at 95% 
and labeled with anti-HPV16 L1 specific antibody followed by the FITC dye (see 
paragraph 3.15.). Expression of L1 protein was observed in cells transfected with 
p16shell plasmid only, while the expression of EGFP was observed in cells co-
transfected with p16shell and pfwb plasmids (figure 9). 
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Figure 9. Immunofluorescence on 293TT transfected cells labeled with specific anti-HPV16 
L1 antibody: negative control (left), cells transfected with p16shell plasmid only (middle), 
expression of EGFP in cells transfected with p16shell and pfwb plasmids (right). 
 
4.1.5. Evaluation of HPV16 L2 protein expression by immunofluorescence 
 
In order to evaluate the expression of HPV16 L2 protein in hygromycin-selected 
293TT cells, cells were transfected with p16shell plasmid. After 48 hours, cells were 
collected, fixed in dimethyl ketone at 95% and labeled with anti-HPV16 L2 specific 
antibody (Santa Cruz Biotechnology), followed by the FITC dye. There was no 
difference between negative control and transfected cells (figure 10). This result was 
not surprising because, as mentioned in NCI-CCR protocols, the expression level of 
L2 protein was demonstrated to be lower as compared to the expression of L1 
protein. 
 
 
 
Figure 10. Immunofluorescence on 293TT transfected cells labeled with specific anti-HPV16 
L2 antibody: negative control (left) and cells transfected with p16shell plasmid (right). 
 
4.1.6. Evaluation of HPV16 L1 protein expression by Western blotting 
 
The expression of HPV16 L1 protein was also evaluated by Western blotting. 293TT 
cells were seeded in 6-well plates at two different concentrations (50.000 and 150.000 
per well) and subsequently transfected with p16shell plasmid. After 48 hours, cells 
were collected and protein concentration was quantified (see paragraphs 3.11. and 
3.12.) Both cells transfected with p16shell plasmid showed the expression of 55 kDa 
HPV16 L1 protein (figure 11). 
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Figure 11. Western blotting analysis performed on 293TT cells transfected with p16shell 
plasmid and labeled with specific anti-HPV16 L1 antibody. 50.000 cells (left column), 
negative controls (two columns in the middle) and 150.000 cells (right column). Most intense 
bands correspond to HPV16 L1 protein of 55 kDa. 
 
 
4.1.7. Evaluation of VLPs transducion ability by flow cytometry 
 
First, 293TT cells were seeded in 6-well plates (200.000 cells per well) and then 
transduced in triplicate with different concentrations of non purified cell lysate 
(concentrated, 1:10, 1:100) containing VLPs. VLPs were obtained after the co-
transfection of p16shell and pfwb plasmids, a maturation step at 37 °C overnight and 
were not purified by Optiprep gradient. After 48 hours, transduced cells were 
harvested and resuspended in phosphate buffer in order to be analysed by flow 
cytometry. Results led to the conclusion that cells transduced with the concentrated 
lysate and with the lysate diluted 1:100 exhibited a comparable level of EGFP 
expression (approximately 30%), while cells transduced with the lysate diluted 1:10 
showed a percentage of EGFP expression equal to 65%. Images obtained by flow 
cytometry analysis are shown in figure 12. 
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Figure 12. Images obtained by flow cytometry on crude lysate containing the VLPs: negative 
controls (left column from the top to the bottom: concentrated, diluted 1:10, diluted 1:100) 
and samples (right column from the top to the bottom: concentrated , diluted 1:10, diluted 
1:100). 
 
 
 
 
 
 
0 50K 100K 150K 200K 250K
FSC-A
0
102
103
104
105
G
FP
-
A
0.13 0
0.02199.9
Concentrato C-
0 50K 100K 150K 200K 250K
FSC-A
0
102
103
104
105
G
FP
-
A
37.3 0
062.7
Concentrato A
0 50K 100K 150K 200K 250K
FSC-A
0
102
103
104
105
G
FP
-
A
0.021 0
6.96e-3100
Diluito 1:10 C-
0 50K 100K 150K 200K 250K
FSC-A
0
102
103
104
105
G
FP
-
A
66.6 0
033.4
0 50K 100K 150K 200K 250K
FSC-A
0
102
103
104
105
G
FP
-
A
0 0
0.015100
FSC-A
250K 0 50K 100K 150K 200K 250K
FSC-A
0
102
103
104
105
G
FP
-
A
26.8 0
073.2
 35 
 
4.1.8. Comparison of VLPs transduction ability on 293TT cells and on 
keratinocytes 
 
The experiment described in the previous paragraph was repeated on 293TT cells 
and keratinocytes, diluting the non-purified VLPs obtained by co-transfection of 
p16shell and pfwb plasmids at different concentrations (1:10, 1:20, 1:40, 1:80 and 
1:160). No EGFP expression was observed in keratinocytes, whereas a gradual 
reduction of EGFP expression was observed in 293TT cells. With VLPs dilutions 
1:80 and 1:160, highest expression levels of EGFP were achieved with percentages 
between 1-25%, as required by the NCI-CCR protocol. These dilutions allowed to 
estimate the VLPs titer in terms of 109 transducing units/ml.  
 
 
 
Figure 13. Images obtained by flow cytometry on the raw lysate containing the VLPs: 
negative control (left), raw lysate diluted 1:80 (middle) and 1:160 (right). 
 
4.1.9. Evaluation of purified VLPs transduction ability in 293TT cells  
 
VLPs obtained after transfection with p16shell and pfwb plasmids on 293TT cells 
were purified by Optiprep gradient (see paragraph 3.9.). DNA content of different 
fractions obtained after stratification on the gradient was estimated by fluorimeter 
(see paragraph 3.10.), while EGFP expression level was assessed by flow cytometry 
(see paragraph 3.14.). Subsequently, 293TT cells were transduced with different 
dilutions of single fractions of VLPs obtained by the gradient. Analysis of single 
fractions by fluorescence microscopy and flow cytometry, showed that fractions with 
highest transducing capability were those between the number 4 and the number 8, 
as defined by the NCI-CCR protocol. These experiments demonstrated that the 
purification step by Optiprep gradient was useful to identify the correct VLP 
fractions. Some images of transduced cells obtained by fluorescence microscope and 
by flow cytometry analysis are reported in figures 14 and 15. 
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Figure 14. Fluorescence microscope images of 293TT cells transduced with fraction 7 
containing purified VLPs: negative control (left), 1:10 dilution (middle) and concentrated 
(right) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Flow cytometry analysis of different fractions containing purified VLPs: negative 
control (top left), fraction 4 (top center), fraction 5 (top right), fraction 6 (bottom left), 
fraction 7 (bottom right). 
 
4.1.10. Evaluation of purified VLPs conformation by SDS-PAGE and Western 
blotting  
 
Optiprep purified fractions of VLPs containing HPV16 L1 and L2 structural proteins 
and expressing EGFP or alternatively SEAP were analyzed by SDS-PAGE under 
non-reducing conditions and by Western blotting using the specific anti-HPV16 L1 
antibody in order to assess the conformation of the virions. In figures 16 and 17, the 
dimeric and the trimeric forms of L1 protein can be appreciated. Moreover, in figure 
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17, the monomeric form of L1 protein can be observed after the treatment with β-
mercaptoethanol. 
 
 
Figure 16. Western blotting performed on fractions purified by Optiprep gradient containing 
the VLPs (consisting of HPV16 L1 and L2 structural proteins and EGFP) after SDS-PAGE 
run in non-reducing conditions. The labeling was performed with specific anti-HPV16 L1 
antibody. Most intense bands correspond to different forms of L1 protein: trimeric (higher 
bands) and dimeric (lower bands). 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Western blotting performed on fractions purified by Optiprep gradient containing 
the VLPs (consisting of HPV16 L1 and L2 structural proteins and SEAP) after SDS-PAGE 
run in non-reducing conditions. The labeling was performed with specific anti-HPV16 L1. 
Bands correspond to different forms of L1 protein: trimeric (higher bands), dimeric 
(intermediate bands) and monomer (lower band). F13** corresponds to F13 reported in 
figure 17, treated with β-mercaptoethanol; F6* corresponds to F6 reported in figure 16. Both 
these fractions were used as positive controls. 
 
 
 
F4 F5 F6 F7 F13 C - marker 
markerF4F5F6F7F8C-C-F6*F13**
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4.2. Set up and standardization of HPV PBNA: summary of results 
 
 
This part of the PhD research activity was focused on better characterization and 
production of HPV16 VLPs, in order to extend the method for other HPV VLP 
types. Co-expression of L2 protein in association with L1 expression was 
demonstrated by SDS-PAGE and Western blotting. Transducing ability and viral 
titer of HPV16 VLPs purified with the less time-consuming method, based on 
polyacrilamide desalting column, was assessed in comparison with Optiprep-
purification. Neutralization experiments were set up by using HPV16 VLPs 
containing EGFP and SEAP reporter plasmids. Percentage of EGFP expression was 
evaluated by flow citometry and by immunofluorescence. Level of SEAP activity was 
evaluated by using SEAP Reporter Gene Assay. In particular, neutralizing effect on 
VLPs was observed by using the positive reference serum at different dilutions 
provided by WHO and  by using heparin at concentration recommended by Human 
Papillomavirus Laboratory Manual (WHO). A comparison between two different 
SEAP detection kits was made on different luminometers provided by Biotek, 
TECAN and BMG, in order to evaluate the most sensitive and precise assay (Roche 
vs Clontech), as well as the most sensitive instrument. After evidences based on first 
set up experiments, neutralization assays were performed by using SEAP Reporter 
Gene Assay (Roche) on different sera, in particular, one collected from an adult 
female, one year after HPV vaccination with GARDASIL®. Neutralizing titer against 
HPV16 was higher than 1:10,240. For the set up of HPV16 neutralization assay, 
specific neutralizing monoclonal antibodies were tested (i.e. D9 and V5). V5 showed 
an excellent neutralizing activity at recommended dilutions (1:20.000 and 1:100.000) 
as expected from reports in the literature (Roden et al., 1997; Day et al., 2007). 
Neutralization assays were performed using VLPs containing structural proteins (L1 
and L2) of the other HPV types 18, 6, and 11. Serum from the vaccinee showed 
neutralizing titer equal to 1:2,560 against HPV18 and HPV6, while the neutralizing 
titer against HPV11 was 1:1,280. VLPs containing non vaccinal high risk HPV types 
sequences (i.e. HPV31, 45, 52, 58) were produced, followed by the setting up of 
specific PBNA in order to evaluate the presence of cross-neutralizing antibodies 
induced by the vaccination. Pilot experiments were made by using sera from vaccinee 
that showed neutralizing effect against HPV31. ELISA assay was also set up in order 
to have data of the whole amount of anti-HPV IgG elicited by vaccination. ELISA 
experiments confirmed and correlated with PBNA results and indicated that the 
vaccine induced a specific immune response against the four vaccinal HPV types.  
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4.2.1. Evaluation of L2 expression in Optiprep-purified VLPs by SDS-PAGE 
and Western blotting  
 
After the assessment of L1 protein, Optiprep-purified fractions of HPV16 VLPs 
were analyzed by SDS-PAGE and Western blotting (see paragraph 3.12.) using a 
specific antibody anti-HPV16 L2 (2JGmab#4, SantaCruz Biotechnology Inc.) in 
order to evaluate the co-expression of L2 protein in association with L1 expression. 
Fractions containing VLPs composed by L2 protein are shown in figure 18. 
 
 
 
Figure 18. Western blotting performed on Optiprep-purified fractions containing HPV16 
VLPs (consisting at structural level of L1 and L2 proteins and containing EGFP reporter 
plasmid) after SDS-PAGE. Blotting was performed with specific anti-HPV16 L2 antibody 
(2JGmab#4).  
 
4.2.2. Assessment of transduction ability of VLPs purified with polyacrylamide 
desalting column 
 
Purification of VLPs obtained by transfection of 293TT cells with p16shell and pfwb 
plasmids was performed also by  polyacrylamide desalting column (Thermo Scientific 
Pierce) (see paragraph 3.9.) in order to compare this method with time-consuming 
Optiprep-purification. DNA content of each fraction was estimated by Quant-iT 
PicoGreen dsDNA assay (see paragraph 3.10.), while EGFP expression level was 
assessed by flow cytometry after transduction of 293TT cells with different fractions 
(see paragraph 3.14.). Analysis of transduced cells by fluorescence microscopy and 
flow cytometry showed that the fractions with higher transducing capability were 
those between numbers 17 and 20. Comparing two purification methods, no 
differences were noticed in viral titer obtained (both were 109 transducing units/ml). 
However, polyacrylamide desalting column resulted the faster purification method in 
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comparison with Optiprep and was applied for the following VLPs purification (i.e. 
HPV6, 11, 18, 31, 45, 52, 58 VLPs containing SEAP reporter plasmid).  
 
4.2.3. PBNA set up  
 
HPV16 VLPs containing EGFP and SEAP reporter plasmids were used to set up 
neutralization experiments by using a specific anti-HPV16 L1 antibody (CamVir-1, 
Santa Cruz Biotechnologies Inc.; dilutions 1:1.000 and 1:10.000) and heparin (1 
mg/ml) as positive neutralization control. HPV16 VLPs with EGFP were diluted 
(1:50, 1:100, 1:300, 1:600, 1:800, 1:1.000, 1:2.000) and incubated onto 293TT cells 
with or without antibody or heparin. Percentage of EGFP expression was evaluated 
by flow citometry and also by immunofluorescence (see paragraphs 3.14. and 3.15.). 
Results are reported in figures 19 and 20. The antibody CamVir-1 was not able to 
neutralize VLPs, while heparin, used as control, blocked VLPs infection. This is due 
to the intrinsic characteristics of the antibody. In fact, this antibody is not able to 
recognize neutralizing epitopes on the VLPs surface.  
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Figures 19 and 20. Neutralization assay performed with HPV16 VLPs containing EGFP 
reporter plasmid in association with specific anti-HPV16 L1 antibody diluted 1:1.000 or 
1:10.000 and heparin. Dilutions of VLPs are reported in the abscissa, while EGFP 
expression percentage is reported in the ordered.  
 
HPV16 VLPs with SEAP were diluted (1:150, 1:500, 1:1.000, 1:10.000) and incubated 
onto 293TT cells with or without heparin at different concentrations (0,1 mg/ml and 
1 mg/ml), as well as with positive reference serum (anti-human papillomavirus type 
16 serum (1st International Standard) WHO International Standard or Reference 
Reagent NIBSC code: 05/134) at different dilutions (1:5, 1:10, 1:20, 1:40). Level of 
SEAP activity was evaluated by using SEAP Reporter Gene Assay (see paragraph 
3.16.). Results are reported in figures 21 and 22. Heparin had greater neutralizing 
effect at the greatest concentration (1 mg/ml) (figure 21). This concentration is 
recommended by Human papillomavirus laboratory manual (WHO/IVB/10.12; 
First edition, 2009). In the second figure (figure 22), neutralizing effect by HPV16 
positive reference serum against HPV16 VLPs is highlighted. 
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Figure 21. Neutralization assays performed with HPV16 VLPs with SEAP reporter plasmid 
in association with HPV16 positive heparin. Dilutions of VLPs are reported in the abscissa, 
while relative light units (RLU) of alkaline phosphatase are reported in the ordered. 
 
 
 
Figure 22. Neutralization assays performed with HPV16 VLPs with SEAP reporter plasmid 
in association with HPV16 positive reference serum. The neutralizing effect by HPV16 
positive reference serum at different dilutions (between 1:5 and 1:40) against HPV16 VLPs is 
shown.  
      
4.2.4. PBNA using different SEAP detection kits and luminometers 
 
A comparison between two different commercial SEAP detection kits (see paragraph  
3.16.) was made on different luminometers provided by Biotek, TECAN, and BMG, 
in order to identify the most sensitive and precise assay (kit by Roche vs kit by 
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Clontech) and the most sensitive instrument. HPV16 VLPs with SEAP reporter 
plasmid were diluted (1:150, 1:500, 1:1.000, 1:10.000) in neutralization buffer and 
three identical neutralization assays were performed. Supernatants were than 
evaluated in parallel with two different SEAP detection kits. SEAP Reporter Gene 
Assay (Roche) gave better results with all three instruments than SEAP 
Chemiluminescence Kit 2.0 Great Escape (Clontech). Taking in consideration both 
detection kits, TECAN luminometer demonstrated higher sensitivity. Results 
reported in RLU are shown in table 1. 
 
VLPs Roche Clontech Roche Clontech Roche Clontech
 1:150 5,59E+05 1,17E+05 6,50E+06 1,04E+06 1628 591
 1:500 2,32E+05 8,29E+04 3,60E+06 6,08E+05 1323 330
 1:1000 2,55E+05 4,04E+04 2,03E+06 3,44E+05 780 185
 1:10,000 2,26E+03 5,04E+02 2,86E+04 3,70E+03 8 3
NEG cntr 3,60E+01 2,20E+01 7,06E+02 5,81E+02 0 2
NB 6,96E+02 1,76E+02 3,64E+03 9,96E+02 3 3
BIOTEK TECAN BMG 
 
 
Table 1. Comparison between different SEAP detection assays (Roche vs Clontech) and 
luminometers (Biotek, TECAN and BMG). 
 
4.2.5. PBNA with vaccinated female serum  
 
After evidences based on first set up experiments, neutralization assays were 
performed by using different sera, in particular, one collected from an adult female, 
one year after HPV vaccination with GARDASIL®. Positive controls of 
transduction onto 293TT cells were VLPs alone. HPV16 positive and negative 
reference sera were provided by NIBSC. The first international standard was an anti-
HPV16 serum (WHO code: 05/134), while the second one was a negative reference 
serum. In PBNA performed with HPV16 VLPs, the vaccinated subject showed a 
neutralizing titer higher than 1:80, as well as the HPV16 positive reference serum. 
The titer is defined as the reciprocal of the highest dilution of serum that reduces the 
SEAP activity by at least 50% in comparison to the reactivity in the wells that 
received VLPs but no antibody. Negative reference serum showed no neutralizing 
effect, as expected. Results are reported in figures 23, 24 and 25. 
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Figure 23. Neutralization of HPV16 VLPs by a vaccinated female serum, collected one year 
after the completion of the vaccination cycle. Neutralizing titer is higher than 1:80, thus 
indicating that HPV vaccination induced a good and specific humoral response.  
 
 
 
Figure 24. Neutralization of HPV16 VLPs by the HPV16 positive reference serum (WHO 
code: 05/134). Neutralizing titer is higher than 1:80, thus indicating that reference serum had 
specific neutralizing antibodies against HPV16.  
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Figure 25. No neutralizing effect on HPV16 VLPs elicited by the negative reference serum. 
 
To evaluate the neutralizing titer against HPV16 of vaccinated female with more 
accuracy, serial dilutions of her serum starting from 1:40 were made. Neutralizing 
titer was higher than 1:10,240, as reported in figure 26. 
 
 
 
Figure 26. Neutralization of HPV16 VLPs by vaccinated female serum, collected one year 
after the completion of the vaccination cycle. Neutralizing titer is higher than 1:10,240, thus 
indicating that HPV vaccination induced a good and specific humoral response.  
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4.2.6. PBNA with specific neutralizing monoclonal antibodies  
 
For HPV16 neutralization assay set up, specific neutralizing monoclonal antibodies 
were tested. Professor Christiansen kindly send us three of them: J4 (anti-HPV18), 
D9 (anti-HPV16) and V5 (anti-HPV16). D9 showed no satisfactory neutralizing 
effect, despite the cross-reactivity between different HPV types declared. V5 showed 
an excellent neutralizing activity at recommended dilutions (1:20.000 and 1:100.000) 
as expected from articles reported in the literature (figure 27). 
 
 
 
Figure 27. Neutralization of HPV16 VLPs with two different monoclonal antibodies (i.e. D9 
and V5). D9 shows no satisfactory neutralizing effect, instead of V5.  
 
4.2.7. PBNA using other HPV types (i.e. HPV types 18, 6, 11) 
 
Neutralization assays were performed using VLPs containing L1 and L2 of other 
HPV types, i.e., HPV18, 6, 11. Heparin was used as a positive control for 
neutralization. In PBNA with HPV18 VLPs, serum from a vaccinated female 
showed neutralizing titer equal to 1:2,560, while negative reference serum showed no 
neutralizing effect (figures 28 and 29). Mild neutralizing effect was observed using 
specific anti-HPV18 monoclonal antibody, J4, at different dilutions (figure 30). 
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Figure 28. Neutralization of HPV18 VLPs with vaccinated female serum, collected one year 
after the completion of the vaccination cycle. Neutralizing titer is equal to 1:2,560. 
 
 
 
Figure 29. No neutralizing effect on HPV18 VLPs by the negative reference serum. 
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Figure 30. Neutralization of HPV18 VLPs with specific monoclonal antibody, J4, at different 
dilutions. Mild neutralizing effect was observed. 
 
In PBNA with HPV6 VLPs, vaccinated female serum showed a neutralizing titer 
equal to 1:2,560, as reported in figure 31. Negative reference serum showed no 
neutralizing effect, as expected (figure 32).  
 
 
 
Figure 31. Neutralization of HPV6 VLPs with a vaccinated female serum, collected one year 
after the completion of the vaccination cycle. Titer is equal to 1:2,560. 
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Figure 32. No neutralizing effect on HPV6 VLPs by negative reference serum. 
 
 
Finally, neutralization was also performed against HPV11 VLPs. Vaccinated female 
serum showed a neutralizing titer equal to 1:1,280, as shown in figure 33. 
 
 
 
Figure 33. Neutralization of HPV11 VLPs with a vaccinated female serum, collected one 
year after the completion of the vaccination cycle. Titer is equal to 1:1,280.  
 
4.2.8. ELISA set up 
 
ELISA for different HPVs L1 were also set up (see paragraph 3.18.) in order to have 
data of the whole amount of anti-HPV IgG elicited from vaccination. Coating was 
performed overnight at 4 °C with different concentrations of HPV16 VLPs (0.5 µg 
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and 1 µg) in PBS solution. Vaccinated female serum was used at dilution 
recommended by WHO Human Papillomavirus Laboratory Manual (i.e. 1:10, 1:31,6, 
1:100). A specific anti-human IgHRP (γchain) antibody was used to detect specific 
human anti-HPV IgG. Best and more specific results were obtained by using the 
concentration of 0.5 µg of VLPs, while good results were also obtained with the 
concentration of 1 µg of VLPs (figures 34 and 35). The absorbance value of negative 
control was lower than 0.2, while the absorbance value of positive serum, which can 
be also considered as a positive control cut-off, was higher than 1. Correlation index 
was higher than 0,95. Therefore, ELISA experiments confirmed and correlated with 
PBNA results and indicated that the vaccine elicited a specific immune response 
against four vaccinal HPV types.  
 
 
 
Figure 34. Results from ELISA performed with an overnight coating of 1 µg of HPV16 
VLPs. 
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Figure 35. Results from ELISA performed with an overnight coating of 0,5 µg of HPV16 
VLPs. 
 
4.2.9. Production of VLPs containing non vaccinal high risk HPV types 
sequences 
 
Different batches of VLPs containing coding sequences of structural viral proteins of 
non vaccinal high risk HPV types, i.e. HPV31, 45, 52 and 58, were obtained by 
transfecting 293TT cells with different HPV plasmids and pYSEAP plasmid 
containing the coding sequence of human placental alkaline phosphatase protein as 
reporter gene (see paragraphs 3.2., 3.7., 3.8.). All these VLPs were purified by using 
polyacrilamide desalting column (see paragraph 3.9.) and fractions were screened by 
L1 content by using NanoDropND 1000 Spectrophotometer at the wavelength of 
280 nm, corresponding to the maximum absorption peak of the peptide bond (see 
paragraph 3.10.). Preparations were stored at -80 °C until use. 
 
4.2.10. PBNA using non vaccinal high risk HPV types VLPs (i.e. HPV types 
31, 45, 52, 58)  
 
Neutralization assays using VLPs containing structural proteins (L1 and L2) of non 
vaccinal high risk HPV types, i.e. HPV31, 45, 52, 58, were set up and used to 
evaluate a vaccinated female serum sample. For all these assays, heparin was used as a 
positive control for neutralization. In PBNA with HPV31 VLPs, serum from the 
vaccinated female showed a neutralizing titer equal to 1:160 (figure 36). For other 
HPV types, no neutralizing effects were observed (figures 37, 38, 39).  
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Figure 36. Neutralization of HPV31 VLPs with a vaccinated female serum, collected one 
year after the completion of the vaccination cycle. Neutralizing titer is equal to 1:160.  
 
 
 
Figure 37. Neutralization of HPV45 VLPs with a vaccinated female serum, collected one 
year after the completion of the vaccination cycle. No neutralizing effect on HPV45 VLPs 
was observed. 
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Figure 38. Neutralization of HPV52 VLPs with a vaccinated female serum, collected one 
year after the completion of the vaccination cycle. No neutralizing effect on HPV52 VLPs 
was observed. 
 
 
 
Figure 39. Neutralization of HPV58 VLPs with a vaccinated female serum, collected one 
year after the completion of the vaccination cycle. No neutralizing effect on HPV58 VLPs 
was observed. 
 
Same neutralization assays were repeated by using a serum sample from a vaccinated 
male. There was no neutralizing effect against HPV31, 45, and 52, but a mild effect 
towards HPV58 (neutralizing antibody titer corresponding to 1:40) (figures 40, 41, 
42, 43).  
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Figure 40. Neutralization of HPV31 VLPs with a vaccinated male serum. No neutralizing 
effect on HPV31 VLPs was observed. 
 
 
 
Figure 41. Neutralization of HPV45 VLPs with a vaccinated male serum. No neutralizing 
effect on HPV45 VLPs was observed. 
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Figure 42. Neutralization of HPV52 VLPs with a vaccinated male serum. No neutralizing 
effect on HPV52 VLPs was observed. 
 
 
 
Figure 43. Neutralization of HPV58 VLPs with a vaccinated male serum. Neutralizing titer is 
equal to 1:40.  
 
4.3. Clinical study to evaluate neutralizing antibodies induced by prophylactic 
HPV vaccines: summary of results 
 
An observational cross-sectional study aiming to evaluate humoral immune 
responses against HPV in adolescents and healthy adults vaccinated with the two 
anti-HPV vaccines, GARDASIL® or CERVARIX™, was designed and started on 
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the 24th October 2011, after approval by ethics committee of Padova University 
Hospital (prot. 2413P). Almost 100% of subjects presented HPV type-specific (i.e. 
HPV16 and 18) neutralizing antibodies after the completion of the quadrivalent 
vaccine, with slight decline of antibody detection rate over time. Lower percentages 
of subjects presented neutralizing antibodies against HPV 6 and 11. Regarding non 
vaccinal high risk HPV types, HPV31 specific cross-neutralizing antibodies were 
observed in 50% of subjects vaccinated with the quadrivalent vaccine. The presence 
of neutralizing antibodies against four HPV vaccinal types was also evaluated in two 
vaccinated males. Finally, considering a group of females vaccinated with the bivalent 
vaccine, all subjects presented higher titers of neutralizing antibodies against HPV16 
and HPV18 than subjects vaccinated with the quadrivalent vaccine. HPV31 cross-
neutralizing antibodies were observed in 100% of subjects, while HPV45 and HPV58 
cross-neutralizing antibodies were observed in small percentages of subjects. None 
presented cross-NAbs against HPV52. 
 
4.3.1. Clinical study protocol to compare GARDASIL® or CERVARIX™ 
immunogenicity in vaccinated subjects  
 
An observational cross-sectional study aiming to evaluate antibody responses against 
HPV in adolescents and healthy adults vaccinated with the two anti-HPV vaccines, 
GARDASIL® or CERVARIX™, was designed and started on the 24th October, 
2011, after approval by ethics committee of Padova University Hospital (prot. 
2413P). 
Several partners were involved:  
- Microbiology and Virology Unit, Padova University Hospital;  
- Department of Histology, Microbiology and Medical Biotechnologies, Padova    
  University; 
- Hygiene and Public Health Unit, ULSS16 Padova; 
- Hygiene and Preventive Medicine Unit, IRCCS Burlo Garofolo, Trieste; 
- Prevention Department ASS4 "Medio Friuli", Udine; 
- Microbiology and Virology Unit, Sant’Orsola Malpighi, Bologna University 
Hospital. 
The duration of the study was 24-months and enrollment of 200 subjects aged from 
12 years (the population of girls for whom free and active HPV vaccination is 
offered) to 45 years (the population of women for whom HPV vaccination is 
indicated) for both vaccines was planned. This study aimed to implement and 
standardize immunoassays in order to detect the immune response induced by HPV 
vaccine and to assess and compare the immunogenicity and cross-protection of HPV 
vaccines offered in Italy, CERVARIX™ and GARDASIL®. The objective of the 
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project was to promote the activation of immunological surveillance of the 
population who received prophylactic HPV vaccine.  
The following primary and secondary goals were defined: 
 1) Standardization, validation and clinical definition of reference intervals of the 
following immunological tests: ELISA and PBNA for the determination of total and 
neutralizing antibodies to HPV, B-cell ELISPOT assay for the measurement of 
memory B-cells, T-cell ELISPOT assay for the measurement of memory T-cells 
induced by vaccination, in order to implement these assays in monitoring protocols 
of HPV vaccination; 
2) Determination of the effectiveness of HPV vaccination (rates of serum conversion 
and development of cell-mediated immune response) in the vaccinated population; 
 3) Collection of data useful for the evaluation of immunological correlates of 
protection; 
 4) Comparison of the immunogenicity and the degree of cross-reaction of 
GARDASIL® and CERVARIX™ vaccines.  
Criteria for inclusion in the study were: female sex, completion of vaccination no 
more than 6 months before, absence of concomitant chronic inflammatory diseases 
and cancer, absence of acute infections. 
Criteria for exclusion from the study were: non-completion of vaccination, the 
presence of neoplastic diseases and chronic inflammatory diseases, pregnancy, male 
sex, fever and other symptoms of active infection. 
Data analysis aimed: 
1) to evaluate the distribution of type-specific total and neutralizing antibody 
titer  against HPV16 and HPV18 in subjects who completed the third 
prophylactic vaccine dose, grouped by age and type of vaccine received; 
2) to detect the positivity rate (the number of women with neutralizing antibody 
titer higher than 1:40), the percentage of subjects vaccinated with HPV L1 
VLPs which were detectable in B-cells and memory T-cells by specific 
ELISPOT assay ("responders"), the induction of cross-neutralizing 
antibodies in vaccinated individuals (positivity rate and neutralizing antibody 
titer); 
3) to compare the immunogenicity and cross-reactivity of the two vaccines 
CERVARIX™ and GARDASIL®. 
 
4.3.2. PBNA in patients with natural infection 
 
As control, the presence of HPV type specific neutralizing antibodies was evaluated 
in the serum of subjects (8 males and 3 females, age range: 24- 47 years old) who 
tested positive for HPV16 or HPV6 in the urethral or cervical swabs (table 2). 
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Patient (n.) HPV infection NAbs titer
1 HPV16 1:2,560
2 HPV6 1:160
3 HPV16 < 1:40
4 HPV16 < 1:40
5 HPV16 < 1:40
6 HPV16 < 1:40
7 HPV16 < 1:40
8 HPV16 < 1:40
9 HPV16 < 1:40
10 HPV16 < 1:40
11 HPV6 < 1:40
 
Table 2. HPV type specific neutralizing antibody titers in patients with HPV16 or HPV6 
natural infection. 
 
In 9 cases of natural infection caused by HPV16, only one subject presented HPV16  
neutralizing antibody titer equal to 1:2,560. In 2 subjects with natural infection 
caused by HPV6, only one presented neutralizing antibody titer equal to 1:160. 
 
4.3.3. PBNA in Gardasil® vaccinated subjects  
 
Neutralization assays were performed on serum samples selected from a group of 
100 subjects (all females; age range: 12-46 years old; mean age: 15,66 years old) 
collected in Veneto Region, where the quadrivalent Gardasil® vaccine was offered. 
The study group included 81 subjects investigated within 1-6 month since the 
completion of the three doses of vaccine and 7, 7, and 5 subjects investigated at 2, 3, 
and 4 years after vaccination, respectively. At 1-6 months after the completion of the 
vaccination cycle, 100% vaccines had neutralizing antibodies (NAbs) against HPV16, 
98,8% had NAbs against HPV18, while 91% had NAbs against HPV6 and 50% had 
NAbs against HPV11. The NAbs titer ranged widely from 1:40 to over 1:10,240 and 
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was lower for NAbs against HPV6 and HPV11 than for NAbs against HPV16 and 
HPV18. A progressive reduction of NAbs titer was observed with time from 
vaccination and, at 4 years from vaccination, 80% of subjects had NAbs against 
HPV16, HPV18 and HPV6, and 60% against HPV11 (table 3).  
 
Time post 
vaccination
HPV 16-NAbs pos HPV 18-NAbs pos HPV 6-NAbs pos HPV 11-NAbs pos
1-6 months 81/81 (100%) 80/81 (98,8%) 20/22 (91%) 6/12 (50%)
24 months 7/7 (100%) 7/7 (100%) 7/7 (100%) 5/7 (72%)
36 months 7/7 (100%) 5/7 (72%) 6/7 (85%) 5/7 (72%)
48 months 4/5 (80%) 4/5 (80%) 4/5 (80%) 3/5 (60%)
 
 
Table 3. Percentages of subjects vaccinated with Gardasil® who presented HPV type-
specific NAbs at different time points after the completion of vaccination. 
 
For the analysis of the results, geometric mean of neutralizing titer (GMT) obtained 
by neutralization assays was calculated. Subjects were divided into groups according 
to the time elapsed between the completion of the vaccination and the neutralization 
assay: 1st year (Figure 44), 2nd year (Figure 45), 3rd year (Figure 46) and 4th year 
(Figure 47). The situation is summarized in figure 48 and table 4.  
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Figure 44. GMT of different HPV type-specific NAbs at one year after the completion of 
vaccination (logarithmic scale). 
 
 
 
Figure 45. GMT of different HPV type-specific NAbs at two years after the completion of 
vaccination (logarithmic scale). 
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Figure 46. GMT of different HPV type-specific NAbs at three years after the completion of 
vaccination (logarithmic scale). 
 
 
 
Figure 47. GMT of different HPV type-specific NAbs at four years after the completion of 
vaccination (logarithmic scale). 
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Figure 48. Histogram summarizing the GMT of HPV type-specific NAbs over the years 
after the completion of the vaccination (logarithmic scale). 
 
Time post 
vaccination
HPV16
(GMT; 95% CI)
HPV18
(GMT; 95% CI)
HPV6
(GMT; 95% CI)
HPV11
(GMT; 95% CI)
1st year 2886 (±881) 1004 (±733) 457 (±1750) 20 (±649)
2nd year 525 (±134) 238 (±204) 238 (±134) 15 (±173)
3rd year 290 (±2788) 21 (±172) 31 (±2788) 13 (±202)
4th year 133 (±273) 33 (±65) 44 (±68) 9 (±19)
 
 
Table 4. GMTs calculated on the basis of HPV type-specific neutralizing titer, with  
confidence interval (CI) of 95%. For the calculation of the GMTs and 95% CI, neutralizing 
antibody titer <1:40 was arbitrarily considered equal to a value of 1. 
 
Neutralizing antibody titers corresponding to four vaccinal HPV genotypes were also 
analyzed one by one. In figures 49, 50, 51 and 52 the progress of the titers as a 
function the time elapsed since the completion of the vaccination.   
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Figure 49. GMT of neutralizing antibodies specific for HPV16 over the years (logarithmic 
scale). 
 
 
 
Figure 50. GMT of neutralizing antibodies specific for HPV18 over the years (logarithmic 
scale). 
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Figure 51. GMT of neutralizing antibodies specific for HPV6 over the years (logarithmic 
scale). 
 
 
 
Figure 52. GMT of neutralizing antibodies specific for HPV11 over the years (logarithmic 
scale). 
 
Low level of cross-NAbs against HPV31 (1:40)  was detected in 50% of the 6 
subjects evaluated at 1-6 months after vaccination, while no cross-NAbs were 
detected against HPV45, HPV52 and HPV58. Results are summarized in table 5. 
 
 65 
 
Time post 
vaccination
HPV 31-NAbs pos HPV 45-NAbs pos HPV 52-NAbs pos HPV 58-NAbs pos
1-6 months 3/6 (50%) 0/6 (0%) 0/6 (0%) 0/6 (0%)
 
 
Table 5. Percentages of subjects vaccinated with Gardasil® who presented, or not, specific 
cross-NAbs against HPV31, 45, 52 and 58. 
 
High-titer neutralizing antibody response after vaccination was also observed in two 
males (age range: 34-41 years old; mean age: 37,5 years old) for all four vaccinal HPV 
genotypes. Results are presented in figure 53.  
 
 
 
Figure 53. Histogram summarizing the GMTs of neutralizing antibody specific for HPV16, 
18, 6 and 11 in vaccinated males.  
 
4.3.4. PBNA in Cervarix™ vaccinated subjects  
 
Neutralization assays were performed on serum samples selected from a group of 6 
subjects (all females; age range: 11-20 years old; mean age: 13,99 years old) collected 
within 1-6 month since the completion of the three doses of vaccine in Emilia-
Romagna Region, where the bivalent Cervarix™ vaccine was offered. At 1-6 months 
after the completion of the vaccination cycle, 100% vaccines had neutralizing 
antibodies against HPV16 and HPV18. Titers were higher than titers observed in 
Gardasil® vaccinated subjects, ranging from 1:10,240 to over 1:20,480. 100% of 
subjects presented also NAbs against HPV31, whereas 16.6% presented cross-NAbs 
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against HPV45 and HPV58.  None presented cross-NAbs against HPV52. Results 
are summarized in table 6 and figure 54. 
 
Time post 
vaccination
HPV 16-NAbs 
pos
HPV 18-NAbs 
pos
HPV 31-NAbs 
pos
HPV 45-NAbs 
pos
HPV 52-NAbs 
pos
HPV 58-NAbs 
pos
1-6 months 6/6 (100%) 6/6 (100%) 6/6 (100%) 1/6 (16.6%) 0/6 (0%) 1/6 (16.6%)
 
 
Table 6. Percentage of subjects vaccinated with Cervarix™ who presented specific NAbs 
against HPV16, HPV18, and specific cross-NAbs against HPV31, HPV45, HPV52 and 
HPV58. 
 
 
 
Figure 54. Histogram summarizing the GMTs of neutralizing antibody for different HPV 
types in Cervarix™ vaccinated females, 1-6 months after the completion of the vaccination.  
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5. DISCUSSION AND CONCLUSIONS 
 
This study investigated the induction of HPV neutralizing and cross-neutralizing 
antibodies in subjects receiving the prophylactic bivalent and quadrivalent HPV 
vaccines. A range of efficacy trials with bivalent and quadrivalent HPV vaccines 
conducted globally demonstrated their high efficacy and immunogenicity (Villa et al., 
2006a; Joura et al., 2008; Schwarz and Leo, 2008; Future I/II Study Group et al., 
2010; Roteli-Martins et al., 2012; Khatun et al., 2012). Nevertheless, immunological 
correlates of protection and quantification of antibody levels required to confer 
protection against HPV have not been defined yet (Stanley et al., 2006; Schwarz and 
Leo, 2008).  
This PhD research study showed high immunogenicity induced by both vaccines in 
adolescent girls and demonstrated a slight decrease in GMTs of NAbs over time in 
subject vaccinated with the quadrivalent vaccine, for whom long-term data were 
available. Seroconversion was observed in approximately 100% of subjects within 
one year after vaccination, combined with the presence of cross-neutralizing 
antibodies against other high risk non-vaccinal HPV types., i.e. HPV31, 45 and 58.  
It’s well known that vaccine-mediated protection against HPV is based on 
neutralizing antibodies induction, in particular against L1 capsid protein (Day et al., 
2007). This protein is the main component of two vaccinal preparations (Gardasil®, 
Cervarix™) that are available on the market since 2006 with the purpose to prevent 
the onset of cervical cancer (Joura et al., 2008). These vaccines are made of virus-like 
particles that are able to stimulate the immune system, promoting the appearance of 
high antibody titers and specific memory immune responses (Paavonen et al., 2007). 
Both have be proven to be effective and safe to prevent HPV16 and 18 related 
CIN2+ or greater lesions and to provide different levels of cross-protection against 
serotypes 31, 33, 45, 52 and 58, not included in the vaccine (Smith et al., 2007; 
Einstein et al., 2011a; Einstein et al. 2011b; Kemp et al., 2011; Kemp et al., 2012; 
Malagón et al., 2012). Their long-term efficacy, however, has not yet been completely 
proven and several gaps in our understanding of the vaccines’ performance remain.  
Vaccine immunogenicity data derive mainly from studies performed by manufacturer 
companies and standardized assays are not commercially available. Pre-clinical data 
suggest that neutralizing antibodies constitute the primary mechanism of protection 
against infection with HPV, thus indicating that measuring the antibody response 
elicited by HPV vaccination should be performed using neutralization assays or, at a 
minimum, assays that correlate with neutralization activity. The use of neutralization 
assays as primary immune readouts for large clinical trials is challenging because 
HPV is unable to grow on monolayer cell culture. Even if the recent introduction of 
PBNA makes the use of neutralization assays possible in the context of clinical trials, 
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PBNA is laborious and difficult to perform, requires considerable expertise and 
experience to standardize, and the detection reagents are very expensive. However, 
the PBNA may be the best available assay to test functional anti-HPV antibodies 
and, as it is independent of vaccine material, is an unbiased method for measuring 
responses to different vaccine VLPs. For all these reasons, PBNA should therefore 
be considered as a benchmark assay for detecting neutralizing antibodies (Dessy et al., 
2008). WHO guidelines for HPV vaccines have also indicated that “neutralization 
assays are considered ‘the gold standard’ for assessing the protective potential of 
antibodies induced by the HPV vaccines"(WHO, 2007; WHO, 2008).  
In this context, we developed and set up two different assays in order to evaluate the 
presence of whole and type-specific antibody response induced by prophylactic HPV 
L1 VLP vaccines. The first method is an ELISA which does not differentiate 
between type-specific conformational antibodies and type-common antibodies, 
which tend to be specific for epitopes presented by denatured L1 capsid protein and 
are usually not neutralizing. The second method is the PBNA, which can 
discriminate between conformational and non conformational epitopes and can 
evaluate the presence of HPV type-specific neutralizing antibodies. Both the direct 
ELISA and the PBNA were used for the assessment and registration of GSK’s 
cervical cancer vaccine, CervarixTM, worldwide (Dessy et al., 2008; Kemp et al, 2012). 
In this PhD research study, different batches of VLPs containing structural proteins 
(L1 and L2) of vaccinal and non vaccinal high risk HPV types, i.e. HPV6, 11, 16, 18, 
31, 45, 52, 58 were produced with high transducing property (109 t.u./ml). First set 
up experiments have been made by employing single HPV-type specific VLPs in 
neutralization assays with sera from a vaccinated female and from a vaccinated male 
one year after vaccination with Gardasil®, in order to make assays reliable and 
reproducible. High HPV type-specific neutralizing antibody titers were observed in 
PBNA, ranging from 1:1,280 against HPV11 to 1:2,560 against HPV18 and HPV6, 
reaching the titer of 1:10,240 against HPV16. Low NAb titers against HPV31 (1:160) 
and HPV58 (1:40) were observed, respectively. Results obtained after different HPV-
type specific PBNA were confirmed with ELISA experiments, thus indicating the 
good correlation between these two methods, as reported (Dessy et al., 2008). The 
measurement obtained with ELISA assay represents a substantial proportion of the 
total immune response to HPV VLP vaccination, as reported by Brown and 
collaborators (Brown et al., 2011). The non-restrictive inclusion of VLP-binding 
antibodies with heterogeneous characteristics as the measured outcome of ELISA 
necessarily reduces the overall assay specificity for a particular subset of the immune 
response, such as neutralizing antibodies. Therefore, using the ELISA measurement 
to represent the HPV protective antibody response is likely an overestimate of the 
level of protective antibodies in vaccinated women (Brown et al., 2011). This is the 
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reason why we decided to perform only PBNA to assess the antibody response  
induced by vaccination in a cross-sectional clinical study on vaccinated subjects, 
enrolled at our clinical study protocol.  
Patients with HPV natural infection established by molecular test in different 
anogenital swabs were evaluated for the presence of HPV type-specific neutralizing 
antibodies in their sera, in order to establish a threshold of humoral immunity 
induced by the virus during natural infection. In two cases, satisfactory NAb titers 
were observed against HPV6 (1:160) and HPV16 (1:2,560), while other patients had 
no detectable neutralizing antibody response. These results confirm studies reporting 
that the immune antibody response induced by natural infection is very weak and not 
all the individuals are able to counteract HPV infection by mounting an effective 
humoral response (Stanley et al., 2006; Stanley et al., 2012).  
In vaccinated subjects, we demonstrated that both the quadrivalent and the bivalent 
vaccines induced high levels HPV type-specific NAbs against vaccine HPV types 16 
and 18. One year after completion of Gardasil® vaccination, 100% vaccinees had 
NAbs against HPV16, 98.8% had NAbs against HPV18, while 91% had NAbs 
against HPV6 and 50% had NAbs against HPV11. NAbs titers ranged widely from 
1:40 to over 1:10,240 and were lower against HPV6 and HPV11 than against HPV16 
and HPV18. One year after vaccination, GMTs ranged from 2886 to 20 and were 
higher for HPV16 and HPV18 than for HPV 6 and HPV11. These values were 
similar to those reported seven months after the completion of quadrivalent HPV 
vaccination by Joura and collaborators (Joura et al., 2008). However, lower GMTs 
were observed in our subjects, in particular for HPV11 as compared with data 
reported by the same research group seven months after the completion of the 
vaccination cycle (Joura et al., 2008). This was probably due to the small number of 
subjects which have been analyzed and to the assay employed for the analysis. Most 
studies, in fact, reported the use of competitive Luminex-based immunoassay (cLIA), 
instead of the gold standard method, PBNA (Villa et al., 2006b; Frazer et al., 2007; 
Olsson et al., 2007; Joura et al., 2008). Among Cervarix™ vaccinated subjects, 
although the sample size was smaller, NAbs titers against HPV16 and HPV18 
reached values over to 1:20,480. Similar data were reported by Einstein and 
collaborators, who observed higher GMTs of anti-HPV16 and 18 serum neutralizing 
antibodies measured in women of 18–26 years old who received the bivalent vaccine 
than in women who received the quadrivalent vaccine (Einstein et al., 2011a). In 
agreement with these findings, a large trial with the bivalent vaccine called 
PATRICIA (The PApilloma TRIal against Cancer In young Adults) demonstrated 
also a high efficacy against CIN2+ lesions associated with HPV16 and HPV18 
infections, against CIN3+ and adenocarcinoma in situ (AIS) irrespective of HPV 
DNA in the lesion (Lehtinen et al., 2012; Roteli-Martins et al., 2012; Szarewski et al., 
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2012). In our series of subjects vaccinated with the quadrivalent vaccine, a 
progressive reduction of NAbs titers over time was observed and, at 4 years after 
vaccination, 80% of subjects had NAbs against HPV16, HPV18 and HPV6, and 60% 
against HPV11. Likewise, Einstein and collaborators observed higher titers of NAbs 
at month 7 and a plateau phase until 24 months for both vaccines. GMTs of anti-
HPV16 and 18 NAbs measured by PBNA in serum remained, however, significantly 
higher up to month 24 in women aged 18–26 years old who received the bivalent 
vaccine than in women who received the quadrivalent vaccine. (Einstein et al., 2011a). 
Follow-up studies on Gardasil® vaccinated subjects reported the decline of 
neutralizing antibody titers 48 months after vaccination in 15-26 years old women 
(Joura et al., 2008), accompanied by the persistence of antibodies up to 60 months 
following initiation of the primary vaccination series in 16-23 years old women 
enrolled in a double-blind, placebo-controlled study (Olsson et al., 2007). According 
Villa and collaborators, quadrivalent vaccine-induced anti-HPV GMTs remained at 
or above those following natural infection, through 5 years (Villa et al., 2006a). High 
GMTs of anti-HPV16 and anti-HPV18 total IgG antibodies in women aged 15-25 
years vaccinated with Cervarix™ were demonstrated during a 5.5 years follow up by 
using ELISA and PBNA (Schwarz and Leo, 2008). More recently, sustained 
immunogenicity and efficacy was reported up to 8.4 years follow-up by Roteli-
Martins and collaborators for the bivalent vaccine (Roteli-Martins et al., 2012). It 
would be interesting to evaluate and compare the efficacy induced by both vaccines 
also in our study. Monitoring of the kinetic profile of NAbs over time for subjects 
vaccinated with Cervarix™ is ongoing in our study.  
Regarding results obtained on cross-neutralization, low level cross-NAbs against 
HPV31 (1:40) was detected in 50% (3/6) of subjects at 1-6 months after quadrivalent 
vaccination, while no cross-NAbs were detected against HPV45, HPV52 and 
HPV58. On the contrary, all subjects (6/6) vaccinated with the bivalent vaccine had 
cross-NAbs against HPV31 and 16.6% (1/6) of them showed cross-NAbs against 
HPV45 and HPV58. None of them presented cross-NAbs against HPV52. Likewise, 
Malagon and collaborators reported higher cross-protective efficacy against HPV31 
and 45 for the bivalent vaccine as compared with the quadrivalent vaccine, in 
particular 77% vs 46% and 79% vs 8%, respectively (Malagon et al., 2012). The 
immune responses induced by two vaccines against HPV31 and HPV45 were also 
compared in an observer-blind study up to month 24, in women who were HPV 
DNA-negative and seronegative prior to vaccination for the HPV type analyzed. 
GMT measured by PBNA and ELISA were found to be similar between vaccines for 
HPV31 and 45. However, according Einstein and collaborators, there was a trend for 
higher seropositivity with the bivalent vaccine (13.0–16.7%) as compared with the 
quadrivalent vaccine (0.0–5.0%) for HPV45 with PBNA, but not with ELISA 
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(Einstein et al., 2011b). Kinetics findings of the antibody response to vaccine cross-
related types HPV31 and HPV45 were confirmed also by Kemp and collaborators 
during a 36 months follow up on Cervarix™ (Kemp et al., 2012). Interestingly, Kemp 
and collaborators observed significant correlations between HPV16 and HPV31 
neutralizing titers and between HPV18 and HPV45 neutralizing titers, despite 100-
fold lower (Kemp et al., 2011). Data from the end-of-study analysis of PATRICIA 
showed that the bivalent vaccine provides also cross-protective efficacy against 6-
month persistent infection and CIN2+ associated with HPV33, HPV31, HPV45, and 
HPV51. Consistent vaccine efficacy for all endpoints across all cohorts was seen only 
for HPV33 (Wheeler et al., 2012). So far, although our study is close to better 
evaluate NAbs titers and cross-NAbs induced by the bivalent vaccine in larger 
sampling, data collected are encouraging and allowed us to make a picture of the 
NAbs response in young females vaccinated against HPV in our Region.  
In conclusion, this study showed that both the quadrivalent and bivalent HPV 
vaccines are immunogenic and induce high titers of NAbs against vaccine HPV 
types, in particular against HPV16 and 18, accompanied by the induction of cross-
NAbs, especially against HPV31. 
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6. ABBREVIATIONS 
 
AIS: adenocarcinoma in situ 
BCA: bicinchoninic acid 
CI: confidence interval 
CIN: cervical intraepithelial neoplasia 
CIS: carcinoma in situ 
cLIA: competitive Luminex immunoassay 
CMI: cell-mediated immunity 
cRIA: competitive radioimmunoassay 
CTL: cytotoxic T lymphocytes  
DMEM: Dulbecco's Modified Eagle Medium 
DNA: deoxyribonucleic acid 
DPBS: Dulbecco's Phosfate-Buffered Saline 
EGFP: enhanced green fluorescence protein 
ELISA: enzyme-linked immunosorbent assay 
ELISPOT: enzyme-linked immunosorbent spot  
EV: epidermodysplasia verruciformis 
FBS: fetal bovine serum 
FITC: fluorescein isothiocyanate 
GMTs: geometric mean antibody titers  
HPV: Human papillomavirus  
HRP: horseradish peroxidase 
HSPGs: heparan sulphate proteoglycans 
IgA: immunoglobulin A  
IgG: immunoglobulin G  
IL: interleukin 
INF: interferon 
kb: kilobases 
kDa: kiloDalton 
LB: Luria-Bertani 
MAb: monoclonal antibody  
NAbs: neutralizing antibodies 
NCI-CCR: National Cancer Institute - Center for Cancer Research 
NMSC: non-melanoma skin cancers 
ori: origin of replication 
PBNA: pseudovirion-based neutralization assay 
PBS: phosphate buffered saline 
PCR: polymerase chain reaction 
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RLU: relative light unit 
RRP: recurrent respiratory papillomatosis  
SDS-PAGE: Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
SEAP: secreted embrionic alkaline phosphatase protein 
SIL: squamous intraepithelial lesions 
SV40: Simian vacuolating virus 40 
TB: Terrific Broth  
TBE: Tris-borate-EDTA buffer 
TBS: Tris-buffered saline  
TLR9: Toll-like receptor 9  
TNF: tumor necrosis factor 
VaIN: Vaginal Intraepithelial Neoplasia 
VIN: Vulvar Intraepithelial Neoplasia 
VLPs: virus-like particles 
WHO: World Health Organization 
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